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Systematic approaches to overcoming limitations  
of MAPK pathway inhibition in melanoma 
 
Abstract 
 
Metastatic melanoma is an aggressive, incurable cancer with historically few therapeutic options.  
The discovery that 60% of melanomas harbor the oncogenic BRAFV600E mutation, which 
constitutively activates the MAPK pathway, has provided a promising new therapeutic axis.  
Although MAPK pathway inhibitor therapy has shown striking clinical results in BRAFV600-
mutant melanoma, this approach faces three limitations.  First, 10-20% of BRAFV600-mutant 
melanomas never achieve meaningful response to MAPK pathway inhibitor therapy (intrinsic 
resistance).  Second, among BRAFV600-mutant melanomas initially responding to MAPK 
pathway inhibitor therapy, relapse is universal (acquired resistance).  Third, approximately 40% 
of melanomas lack BRAFV600 mutations and so are not currently candidates for MAPK pathway 
inhibitor therapy.  We sought to address each of these problems: by characterizing the 
phenomenon of intrinsic MAPK pathway inhibitor resistance, by finding ways to perturb 
mechanisms of acquired MAPK pathway inhibitor resistance, and by identifying novel 
dependencies in melanoma outside of the MAPK pathway.  Intriguingly, the NF-κB pathway 
emerged as a common theme across these investigations.  In particular, we establish that MAPK 
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pathway inhibitor sensitive and resistant melanomas display distinct transcriptional signatures.  
Unlike most BRAFV600-mutant melanomas, which highly express the melanocytic lineage 
transcription factor MITF, MAPK pathway inhibitor resistant lines display low MITF expression 
but high levels of NF-κB signaling.  These divergent transcriptional states, which arise in 
melanocytes from aberrant MAPK pathway activation by BRAFV600E, remain plastic and 
mutually antagonistic in established melanomas.  Together, these results characterize a 
dichotomy between MITF and NF-κB cellular states as a determinant of intrinsic sensitivity 
versus resistance to MAPK pathway inhibitors in BRAFV600-mutant melanoma.  In separate 
investigations, we have shown that, NFKB1 p105, a member of the NF-κB family, intimately 
regulates levels of COT, a known effector of resistance to MAPK pathway inhibitors.  Moreover, 
we have used shRNA screening to nominate particular nodes within the NF-κB pathway, 
including MYD88 and IRF3, as candidate melanoma lineage-specific dependencies.  
Cumulatively, although these studies use diverse approaches to investigate the limitations of 
MAPK pathway inhibitor therapy in melanoma, they converge in nominating the NF-κB 
pathway as a previously underappreciated feature of melanoma biology and suggest the 
relevance of this pathway for future investigation. 
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CHAPTER 1.  INTRODUCTION 
Clinical aspects of melanoma 
Unlike other skin cancers, melanoma is an aggressive and clinically intractable disease.  
Melanoma is the sixth most common cancer in the North America, and the incidence of 
melanoma has increased dramatically over the past several decades [1], suggesting the need for 
better prevention, screening, and therapeutic approaches. 
Melanoma risk factors 
Melanoma risk is partly environmental and partly genetic.  The primary environmental risk 
factor for melanoma, at least in non-Hispanic whites, is UV exposure.[2]  Genetically, 
approximately 10% of melanoma cases are familial [3].  High-risk loci for inherited melanoma 
include CDKN2A [4, 5] in which loss of function mutations impair inhibition of the cyclin-
dependent kinase CDK4 and cell cycle progression; CDK4 itself, in which mutations render it 
unable to be inhibited by CDN2A [6]; and Rb [7, 8].  Other genetic factors have also been 
recently associated with melanoma risk, including MC1R mutations conferring redheadedness 
(even in the absence of UV exposure) [9, 10], MITF mutation (rendering it defective in 
SUMOylation) [11], and promoter mutations in TERT (putatively leading to enhanced TERT 
transcription) [12]. 
Melanoma growth phases 
Phenotypically, melanoma behavior is divided into two growth phases: radial and vertical.  
Radial growth phase melanomas are thin, epidermal, and relatively slow growing.  After a 
variable (or no) period in radial growth phase, melanomas enter vertical growth phase, invading 
into the dermis and gaining metastatic potential.  Once in vertical growth phase, the probability 
of metastasis is directly correlated with depth of invasion (Breslow depth). [13]  It is a measure 
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of the aggressiveness of melanoma that it is perhaps the only cancer where a primary tumor 
measured in millimeters at the time of excision is nonetheless likely to be fatal. 
Melanoma histologies 
Histologically, melanomas are divided into superficial spreading melanoma (the most common 
type, accounting for around 75% of melanomas), nodular melanoma (which progresses 
immediately into vertical growth phase), lentigo maligna melanoma (arising as macular lesions 
on aged, sun-damaged skin), and acral lentiginous melanoma (arising on palmar, plantar, and 
subungual surfaces).[14]  Other rare classes of melanoma exist, including desmoplastic 
melanoma, which features spindle-shaped cells and a lack of MITF staining.[15-17].  However, 
these histologic subtypes do not directly correlate with clinical behavior. 
Conventional treatment options for melanoma 
Conventional treatment options for melanoma include surgery and chemotherapy.  For primary 
melanoma in which complete resection can be achieved, surgical excision is curative.[18]  Once 
metastasis has occurred, however, the mainstay of therapy has traditionally been cytotoxic 
chemotherapy.  However, the standard agent, dacarbazine, has never been shown to have clinical 
benefit in metastatic melanoma relative to no treatment.[19]  As a result, the median overall 
survival for metastatic melanoma has historically been approximately 6 months.[20]  
Genomic landscape of melanoma 
The historically dire therapeutic situation for metastatic melanoma has suggested the importance 
of a comprehensive understanding of oncogenic alterations in melanoma in order identify more 
effective therapeutic options. 
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Mutations 
The most biologically significant mutations in melanoma appear to be those activating the 
MAPK pathway (Ras → RAF → MEK → ERK).  Of these, the most common are activating, 
oncogenic mutations in codon 600 (V) of BRAF.  (These alleles, commonly encoding mutations 
to residues E, D, or K, will hereafter be referred to collectively as BRAFV600 mutant.) [21] 
BRAFV600 mutations permit BRAF to signal even in the absence of normally required upstream 
stimulus from Ras.  Therefore, BRAFV600 mutations constitutively activate the MAPK pathway.  
This effect is oncogenic in melanoma; moreover, in melanoma cell lines harboring the mutation, 
BRAFV600E is required for sustained ERK phosphorylation and cell division. [22-24] 
However, BRAF is not the only MAPK pathway derangement in melanoma: around one-third of 
melanomas harbor activating NRAS mutations. [25, 26]  Notably, NRAS mutations are mutually 
exclusive with BRAFV600 mutations, implying either redundancy or even possibly synthetic 
lethality between these two oncogenes.  The remainder of melanomas have generally been 
considered MAPK pathway wildtype; however, a recent report has demonstrated activating MEK 
mutations in some BRAF-mutant, NRAS-mutant, and BRAF-wildtype/NRAS-wildtype, 
suggesting that at least some melanomas previously characterized as MAPK pathway wildtype 
may in fact have MAPK activation at the level of MEK. [27]  
Regardless of how the MAPK pathway is activated, it is clear—particularly in BRAFV600-mutant 
melanoma—that sustained ERK activation drives continued melanoma proliferation and 
survival.  The canonical role of ERK is to drive transcriptional output by phosphorylating 
transcription factors.  While the transcriptional factors dependent on activation by ERK in 
melanoma have yet to be systematically characterized, among the most important so far appears 
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to be MITF, a master melanocyte regulator and melanoma oncogene discussed in greater detail 
below.   
Recent sequencing studies have revealed other noteworthy mutations in melanoma: oncogenic 
mutations in the histone acetyltransferase co-activator TTRAP, apparent loss-of-function 
mutations in the glutamate receptor GRIN2A [28], loss-of-function oncogenic mutations in the 
PTEN-interacting protein PREX2 [29], and a highly recurrent mutation in the small GTPase 
RAC1 [30].  Perhaps most strikingly, highly recurrent (~70% prevalence) mutations have been 
identified in the TERT promoter, generating gain-of-function consensus ETS binding sites and 
potentially upregulating TERT transcription. [12, 31]  Nonetheless, in contrast to mutations 
affecting the MAPK pathway, functional understanding of these mutations is generally either 
preliminary or nonexistent, and these mutations have not yet been therapeutically targeted in 
melanoma. 
Certain other recurring themes have been noted in recent melanoma sequencing studies.  First, 
the mutation rate among melanomas is highly variable (over nearly two orders of magnitude) and 
is approximately proportional to estimate sun exposure.  Second, particularly in melanomas from 
sun-exposed lesions, the mutation rates observed (up to 100 mutations/Mb) are among the 
highest of cancers so far sequenced.  Finally, for melanomas arising on sun-exposed surfaces, 
there is a highly significant excess of C→T or G→A transitions. [27, 30, 32-34] This mutational 
signature is consistent with that generated by UV irradiation and emphasizes the causal role of 
UV exposure in melanoma development.   
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Copy number 
Copy number alterations in melanoma have been extensively characterized.  Among the most 
frequent targets of deletion are the tumor suppressors PTEN and CDKN2A, whereas TERT and 
CCND1 are frequent targets of amplification.  [27, 30, 35] 
MITF in melanoma 
Perhaps the canonical melanoma copy number alteration is amplification of the transcription 
factor MITF.  This amplification is found in approximately 10-20% of melanomas, although it 
may be essential even in melanomas not harboring amplification [34, 36]  Extensive work over 
the past several decades has characterized the MITF transcription factor as the master regulator 
of the melanocyte lineage (reviewed in [37]).  In melanocytes, MITF orchestrates the 
transcriptional program associated with pigment production and tanning in response to UV 
irradiation (reviewed in [38]).  In melanoma, MITF also has oncogenic functions distinct from is 
pigmentation role.  It drives cell cycle progression by directly inducing CDK2 transcription [39] 
and bypasses senescence in nevi by suppressing expression of CDKN1A and CDKN2A [40].  
Moreover, MITF potentiates cellular survival and evasion of apoptosis by inducing the 
expression of BCL2 [41] and BIRC7 [42].  Thus, MITF is not only a key regulator of normal 
melanocyte biology, but also an important melanoma oncogene. 
The NF-κB pathway 
Although the NF-κB pathway has not generally been considered critical in melanoma, it emerged 
as a recurring theme in our studies.  Therefore, a brief background is presented on it here. 
Overview of the NF-κB pathway 
An overview diagram of the NF-κB pathway is presented in Fig 1.1. 
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Figure 1.1. Schematic of the NF-κB pathway.   
The NF-κB pathway can be divided into 3 arms, each incorporating different upstream 
ligands, adapter proteins, signal transduction networks, and downstream transcription factors.  
See text for more complete description.  
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The NF-κB family includes five transcription factors—RelA (p65), RelB, c-rel, NFKB1 
(p105/p50), and NFKB2 (p100/p52)—that function as dimers.  Because NFKB1/2 lack 
transcriptional activation domains, they drive transcription only when heterodimerized with a Rel 
protein.  NFKB1 and NFKB2 have a C terminal inhibitory ankyrin repeat domain, which masks 
a nuclear localization signal and must be removed to allow nuclear localization and transcription.  
In contrast, inhibition of the Rel proteins is accomplished by the IκB proteins, which contain 
ankyrin repeats homologous to the C terminal of NFKB1/NKFB2.  After upstream pathway 
activation, IκBs are phosphorylated and degraded at the proteasome, releasing Rel-containing 
NF-κB dimers for transcriptional activity.  [43-45]  
NF-κB dimers and their upstream activation can be divided into two pathways, canonical and 
non-canonical. [46] The canonical pathway favors RelA/NFKB1 dimers, whereas the non-
canonical pathway includes RelB/NFKB2 dimers.  In the canonical pathway, IκB is marked for 
degradation by phosphorylation by the IκB kinase IKK-β.  IKK-β is activated by many upstream 
stimuli: for example, IL-1β and LPS signal through their receptors to MYD88 to IRAK1/2/4, 
TRAF6, and the TAB/TAK complex or ECSIT to IKK-β.  IKK-β subsequently phosphoactivates 
NFKB1 and RelA.  A MYD88-independent arm of the non-canonical pathway transduces signals 
from TLR3 ligands (e.g., viral dsRNA) through IKK-ε to the transcription factor IRF3.  The non-
canonical pathway, by contrast, depends on IKK-α, which is phosphoactivated by NIK [46] 
downstream of receptors such as the lymphotoxin β receptor (LTBR). [47]  
NF-κB activation can have diverse consequences.  Two relevant for cancer are control of cell 
cycle progression and induction of anti-apoptotic factors.  NF-κB activity directly drives cell 
cycle progression because the promoter of cyclin D1 contains an NF-κB binding site.  As regards 
apoptosis, NF-κB can drive transcription of anti-apoptotic genes such as BCL2 and BCL-XL.   
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The NF-κB pathway in cancer 
The cancer relevance of NF-κB was first suggested by the fact that the v-rel Avian 
reticuloendotheliosis virus encodes a modified, oncogenic version of c-rel.  [48-51]  Many 
cancers also carry alterations in endogenous NF-κB genes.  For example, diffuse large B cell 
lymphoma (DLBCL) harbors diverse NF-κB derangements including Rel amplification [52-54], 
constitutively active B cell receptor/CARD11 signaling [55-57], and loss of the NF-κB inhibitory 
protein A20/TFNAIP3 [58-60].  In solid tumors, one example is the status of IKBKE as a breast 
cancer oncogene. [61]  Even in the absence of genomic derangements in the NF-κB pathway, 
there may exist latent NF-κB dependency.  While activated Ras drives NF-κB activation [62-65], 
Ras-transformed cells also require NF-κB activity to survive the oncogenic stress of Ras 
activation and transformation [66-68].   Thus, NF-κB appears to play an important role in many 
types of cancer. 
The NF-κB pathway in melanoma 
Despite its roles in other cancers, the NF-κB pathway has been relatively little studied in 
melanoma.  Some melanoma cell lines and tumors show increased activity of IKK-α, IKK-β, 
RelA, and NFKB1 p50 [69-71], with activation correlating with disease-specific mortality.[72]  
NIK—the kinase that activates IKK-α in the non-canonical pathway—is highly expressed in 
melanoma and apparently driven by ligand-independent signaling downstream of LTBR [73, 74]  
In an HRASV12 / p16INK4A mouse model of melanoma, NF-κB activity was required for tumor 
formation; similar results have also been obtained with xenografts and IKK-β inhibitors. [75-77]  
However, to date, there has been no comprehensive assessment of the role of the NF-κB pathway 
in melanoma. 
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Targeted therapeutic approaches to melanoma 
At present, two broad class of targeted therapeutic agents exist in melanoma: immune 
modulatory agents, and MAPK pathway inhibitors.   
Immune modulatory agents 
Immune modulatory agents operate on the principle that melanoma is a highly antigenic cancer. 
[78]  Although there often exists a host immune response against melanoma, it is typically not 
sufficient to contain the tumor.  Therefore, enhancing the anti-tumor immune response has the 
potential to generate therapeutic benefit.  The most successful such approach to date has been 
blockade of immune checkpoints inhibiting T-cell activation, leading to enhanced tumor killing 
by cytotoxic T cells. This strategy, exemplified by ipilimumab (targeting the T cell inhibitor co-
receptor CTLA4) [79, 80] and anti-PDL1 antibodies (targeting PD1/PDL1 interaction) [81], has 
recently shown significant clinical promise in melanoma ([82, 83], reviewed in [84]).  However, 
immune modulatory therapies are not the focus of this work.   
MAPK pathway inhibition 
In contrast, this dissertation focuses on the potential as well as the limits of MAPK pathway 
inhibition.  The rationale for MAPK pathway therapeutics in melanoma comes from two 
fundamental discoveries.  First was the elucidation that that approximately 60% of melanomas 
harbor the activating, oncogenic BRAFV600E mutation, which constitutively activate the MAPK 
pathway.[21] This biological discovery was translated to therapeutic implication by the 
discovery that BRAFV600E mutation predict sensitivity to MAPK pathway inhibitors.[85]   
Ultimately, these discoveries were brought to fruition by the development of vemurafenib 
(PLX4032; its preclinical analogue PLX4720 was used in these studies), a specific inhibitor of 
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V600-mutant BRAF. [86]  In Phase II and III trails in BRAFV600-mutant melanoma patients, 
vemurafenib has achieved clinical benefit in 80-90% of patients and RECIST responses in 
approximately 50% of patients, yielding approximately 7 months progression-free survival and 
lengthening overall survival to approximately 16 months. [87, 88] An improvement on this 
approach has been to combine RAF inhibition with MEK inhibition to achieve more complete 
blockade of the MAPK pathway; in this regime, trials of dabrafenib (a RAF inhibitor) plus 
trametinib (a MEK inhibitor) have yielded response rates approaching 75% and progression-free 
survival of 9.4 months.[89]  Thus, MAPK pathway inhibition has shown significant clinical 
efficacy in BRAFV600-mutant melanoma. 
Limitations to MAPK pathway inhibition 
Resistance to MAPK pathway inhibition 
This advance, however, has been tempered by two realizations.  First, a subset of melanoma 
patients, despite harboring BRAFV600 mutations, do not respond to MAPK pathway therapeutics.  
[87-89] This phenomenon is termed intrinsic resistance.  Second, of those patients who do 
initially respond, all will eventually relapse. [87]  This phenomenon is termed acquired 
resistance.   
Because of its profound clinical relevance, resistance to MAPK pathway inhibition has garnered 
significant research interest.  Cumulatively, a picture of acquired resistance mechanisms has 
begun to emerge.  A common theme in resistance to targeted therapeutics is drug target 
alterations; indeed, aberrant BRAF splicing can generate a truncated version of BRAF, resistant 
to inhibition by PLX4720, that is capable of aberrant self-dimerization and activation. [90]  
Alternatively, instead of re-activating BRAF, other kinases—including CRAF [91] and COT 
[92], a MAP3K—can substitute for BRAF and reactivate pERK.  Resistance can also be 
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achieved by driving flux through the MAPK pathway in a BRAFV600-independent fashion.  
Specifically, signaling from upstream Ras appears to proceed primarily through CRAF rather 
than BRAF.  Therefore, even in the context of BRAFV600E inhibition, Ras activation can restore 
MAPK pathway activity and viability.  Thus, gain of NRAS mutation [93], loss of NF1 [94] (a 
negative regulator of Ras), or loss of MAPK-driven negative feedback onto Ras [95] leads to 
BRAF-independent signaling flux into the MAPK pathway and inhibitor resistance.  Similarly, 
driving endogenous signaling through Ras by HGF stimulus (whether exogenous or supplied by 
tumor stroma) of the upstream receptor kinase MET can cause resistance. [96] Conversely, 
inhibition of BRAF becomes ineffective if the normal output of BRAF is restored.  Thus, 
activating alleles in MEK that re-activate pERK in a BRAF-independent fashion are sufficient to 
cause resistance [97]; moreover, even below the level of ERK, re-engagement of the MAPK 
transcriptional output BCL2A1 confers resistance. [98]  
Together, these studies have begun to paint a unified picture of acquired resistance to inhibition 
of BRAFV600E in melanoma.  Two points are important to note.  First, these studies have largely 
identified mechanisms that reactive either the MAPK pathway or its output; in other words, 
resistance to MAPK inhibition in these cases occurs because the MAPK pathway or its output is 
no longer effectively inhibited.  Second, these studies have largely begun from the premise of 
making a resistant cell sensitive; thus, they are conceptually targeted towards characterization of 
acquired, rather than intrinsic, resistance.  For these reasons, the extent to which non-MAPK 
pathway mechanisms of resistance might be relevant, particularly in the setting of intrinsic 
resistance, remains to be elucidated. 
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Context for the current work 
Thus, despite its promise, MAPK pathway inhibition in melanoma faces three fundamental 
limitations.  First, 10-20% of BRAFV600-mutant melanomas are intrinsically resistant to MAPK 
pathway inhibition.  Second, of the 80-90% of BRAFV600-mutant melanomas who initially 
respond to MAPK pathway inhibition, all will eventually acquire resistance and relapse.  Third, 
for both those melanomas harboring BRAFV600 mutations as well as those lacking them, durable 
control is likely to require the identification of therapeutically tractable vulnerabilities beyond 
the MAPK pathway.  In this work, we sought to address each of these issues in a systematic 
fashion. 
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CHAPTER 2.  UNDERSTANDING INTRINSIC MAPK PATHWAY INHIBITOR RESISTANCE:  
AN MITF/NF-ΚB MELANOMA CELL STATE DICHOTOMY INFLUENCES SENSITIVITY TO MAPK 
PATHWAY INHIBITORS.   
 
Abstract 
Most melanomas harbor the oncogenic BRAFV600E mutation, which constitutively activates the 
MAPK pathway.  Although MAPK pathway inhibition has shown clinical benefit in BRAFV600-
mutant melanoma, 10-20% of patients fail to respond to this approach.  Using a panel of 
BRAFV600-mutant melanoma cell lines, we found that MAPK pathway inhibitor sensitive and 
resistant melanomas display distinct transcriptional profiles.  Whereas most BRAFV600-mutant 
melanoma cell lines showed high expression of the melanocytic lineage transcription factor 
MITF and its target genes, MAPK pathway inhibitor resistant lines displayed low MITF 
expression but high levels of NF-κB signaling.  Clinically, melanomas with low pre-treatment 
MITF expression showed less durable responses to MAPK pathway inhibitor therapy.  In 
melanocytes, establishment of a cell state characterized by robust NF-κB-related gene expression 
was achieved by introduction of BRAFV600E but blocked by activation of MITF.  Moreover, in 
established melanoma cell lines, this cellular state is plastic; MITF expression antagonized 
maintenance of the NF-κB transcriptional state, whereas NF-κB activation antagonized MITF 
expression and induced both resistance marker gene expression and MAPK pathway inhibitor 
resistance.  These results suggest that a dichotomy between MITF and NF-κB transcriptional 
states in BRAFV600-mutant melanoma may influence intrinsic resistance to MAPK pathway 
inhibitors. 
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Introduction 
The discovery that activating BRAFV600 mutations (present in 50-60% of melanomas) [21] 
predict sensitivity to mitogen-activated protein kinase (MAPK) pathway inhibition [85] has 
revolutionized therapeutic approaches to melanoma.  MAPK pathway inhibitors—including the 
RAF inhibitors vemurafenib and dabrafenib and the MEK inhibitor trametinib—achieve clinical 
benefit in 80-90% of BRAFV600-mutant melanoma patients, with RECIST response rates between 
50% (for vemurafenib alone) and 70% (for dabrafenib+trametinib) ([87, 89, 99].  However, 
among patients whose tumors respond to MAPK pathway inhibitors, relapse is universal 
15 
 
(acquired resistance); moreover, 10-20% of patients never achieve meaningful response to 
therapy (intrinsic resistance).  Recent studies have characterized diverse mechanisms of acquired 
resistance to MAPK pathway inhibitors in BRAFV600-mutant melanoma.[90-92, 94-98] In 
contrast, we sought to elucidate molecular features that might contribute to intrinsic resistance to 
MAPK pathway inhibition in BRAFV600-mutant melanoma.   
Results 
1. Association of expression classes with differential MAPK pathway inhibitor sensitivity in 
BRAFV600-mutant melanoma. 
We hypothesized that cell-intrinsic features such as gene expression programs might partly 
account for intrinsic resistance to MAPK pathway inhibitors.  To test this hypothesis, we 
examined 29 BRAFV600-mutant melanoma cell lines from the Cancer Cell Line Encyclopedia 
[100] for which gene expression and pharmacological sensitivity data was available (Fig. 2.1A).  
Although most lines were sensitive to the RAF inhibitor PLX4720 (GI50 < 2 uM), a subset 
exhibited intrinsic resistance to this agent as well as to MEK inhibitors (PD0325901 and 
AZD6244, Fig. 2.1B).  Using this panel, we identified genes whose expression across the cell 
lines was strongly correlated or anti-correlated with their PLX4720 GI50 values.  MITF, which 
encodes a melanocyte lineage regulatory transcription factor and melanoma oncogene [36], 
emerged as the single gene best correlated with sensitivity to PLX4720 (Fig. 2.1B, 2.1C, 2.2).  
Conversely, MITF, its target genes, and a transcriptional signature of MITF activity [11] were 
poorly expressed in the resistant lines.  Instead, intrinsically resistant BRAFV600E melanoma cell 
lines expressed gene sets associated with NF-κB activation, as well as individual marker genes 
including AXL, TPM1, NRP1, and CDH13.  (Fig. 2.1B, 2.1C) 
16 
 
This reciprocity between MITF and NF-κB transcriptional profiles, which correlated with MAPK 
inhibitor sensitivity in BRAFV600-mutant melanoma cell lines, was reminiscent of prior 
transcriptional [101] and histopathologic [102] analyses of melanoma tumors.  However, links to 
intrinsic vemurafenib or dabrafenib/trametinib resistance in BRAFV600-mutant melanomas have 
not previously been defined.  The reciprocity between MITF and NF-κB expression signatures 
was confirmed using a collection of primary and metastatic BRAFV600-mutant melanomas (Fig. 
2.1D) (data from The Cancer Genome Atlas, https://tcga-data.nci.nih.gov/tcga/).  Thus, the 
transcriptional class distinction that distinguished MAPK pathway inhibitor sensitive and 
resistant cell lines in vitro was also readily discernible in vivo.  Cumulatively, these results 
nominate an expression dichotomy between NF-κB and MITF, present in both melanoma cell 
lines and tumors, as correlated with intrinsic resistance versus sensitivity to MAPK pathway 
inhibition. 
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Figure 2.1. Association of expression classes with differential MAPK pathway inhibitor 
sensitivity in BRAFV600-mutant melanoma.   
(a) PLX4720 sensitivity across a collection of BRAFV600-mutant melanoma cell lines.   
(b) Relationship between PLX4720 sensitivity and MITF-high versus NF-κB-high classes.   
(c) Expression of selected markers by Western blot.   
(d) Expression dichotomy in BRAFV600-mutant melanoma tumor samples.  
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Figure 2.2. 
Correlation of MITF expression with MAPK pathway inhibitor sensitivity in a panel of 29 
BRAF
V600
-mutant melanoma cell lines. 
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2. NF-κB-high/MITF-low melanomas represent a reproducible subclass distinguished by 
resistance to MAPK pathway inhibition 
To verify the association between the MITF/NF-κB class distinction and sensitivity to MAPK 
pathway inhibition, we examined a collection of patient-derived BRAFV600-mutant melanoma 
short-term cultures for which gene expression data, but not pharmacological sensitivity data, was 
available.  As in other datasets, we identified the MITF and NF-κB signatures at both the 
transcriptional (Fig. 2.3A) and protein expression (Fig. 2.4) levels.  We then performed 
pharmacologic growth inhibition studies on 7 “MITF-high” and 3 “NF-κB-high” short-term 
cultures.  Notably, all 7 MITF-high/NF-κB-low short-term cultures were sensitive to RAF and 
MEK inhibition, whereas each of the three NF-κB-high/MITF-low short-term cultures were 
resistant to these agents (Fig. 2.3B).  These finding supported the premise that the MITF-low, 
NF-κB-high transcriptional signature correlated with intrinsic resistance to MAPK pathway 
inhibition in BRAFV600-mutant melanoma. 
In addition to single-agent RAF and MEK inhibitor resistance, we found that MITF-low, NF-κB-
high short-term cultures (Fig. 2.3B) and cell lines (Fig. 2.5) also showed resistance to both 
combined RAF+MEK inhibition and ERK inhibition.  The intrinsic resistance phenotype was not 
attributable to an inability of these agents to suppress MAPK pathway signaling, because the 
reduction of ERK phosphorylation in these lines was comparable to that observed in drug-
sensitive lines (Fig. 2.3C, 2.4, 2.6).  These findings suggest that a molecularly definable subset 
of MITF-high, NF-κB-low BRAFV600-mutant melanomas are “indifferent” to MAPK pathway 
inhibition.   
To assess whether the resistance phenotype linked to this class distinction in vitro might be 
similarly evident in melanoma tumors, we examined a series of pre-treatment biopsy specimens 
21 
 
obtained from metastatic BRAFV600-mutant melanoma patients, subsequently treated with 
combined RAF/MEK inhibition, for whom clinical response data was available.  Using AXL 
expression as a proxy for the NF-κB-high cellular state (Fig. 2.1B-D, 2.3A, 2.4), we stratified the 
cohort into MITF-high/NF-κB-low (n=4) and MITF-low/NF-κB-high (n=8) groups on the basis 
of immunohistochemistry (Fig. 2.3D, 2.7, Table 2.1).  Following dabrafenib + trametinib 
therapy, progression-free survival was significantly shorter (median 5.0 months versus 14.5 
months, p=0.0313) in the MITF-low/NF-κB-high group (Fig. 2.3E), thus providing preliminary 
support for the therapeutic relevance of this molecular dichotomy.   
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Figure 2.3. NF-κB-high, MITF-low melanomas represent a reproducible subclass 
distinguished by resistance to MAPK pathway inhibition  
(a)  Expression dichotomy in BRAFV600-mutant melanoma short-term cultures.   
(b) Relationship between expression class and MAPK pathway inhibitor sensitivity in short-
term cultures.   
(c) Effects of MAPK pathway inhibitors on pERK and pFRA1 across sensitive and resistant 
cell lines.  Uniquely, RPMI-7951 harbors amplification of MAP3K8 (COT), which is known 
to re-activate the MAPK pathway.  D, DMSO; P, 2 µM PLX4720; A, 200 nM AZD6244; 
P+A, PLX4720+AZD6244; E, VTX11, 2 µM.  
(d) Examples of AXL and MITF expression in pre-treatment melanoma biopsies.  
(e) Comparison of progression-free survival between MITF-positive/AXL-negative and 
MITF-negative/AXL-positive classes. 
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Figure 2.4. 
Basal ERK phosphorylation and MITF/NF-κB marker expression in MAPK pathway inhibitor 
sensitive and MAPK pathway inhibitor resistant melanoma short-term cultures. 
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Figure 2.5. 
Sensitivity profile of selected melanomas to inhibition of BRAF (PLX7420), MEK 
(AZD6244), RAF+MEK, and ERK (VTX11E). 
Figure 2.6. 
Basal MAPK pathway activity, as measured by pERK, pS6, and pFRA1, in MAPK pathway 
inhibitor sensitive and MAPK pathway inhibitor resistant melanoma cell lines. 
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  MITF AXL 
sample PFS (mo) distribution  intensity distribution 
 
intensity 
R4 5 diffuse 2 negative 0 
R9 12 diffuse 1 negative 0 
6A 21 diffuse 3 negative 0 
19A 17 diffuse 2 negative 0 
9A 7 negative 0 diffuse 2 
R8 2 negative 0 focal 2 
R10 3 negative 0 focal 2 
11A 10 negative 0 focal 2 
13A 9 negative 0 diffuse 2 
22A 3 negative 0 focal 2 
25A 3 negative 0 focal 2 
12A 12 negative 0 diffuse 2 
Figure 2.7. 
Immunocytochemistry for MITF and AXL in MAPK pathway inhibitor sensitive and resistant 
melanoma cell lines. 
Table 2.1.   
Pre-treatment immunohistochemistry results and progression-free survival (PFS) following 
dabrafenib + trametinib therapy. 
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3. Establishment of two-class dichotomy in melanocytes. 
Having observed that sensitivity and resistance to MAPK pathway inhibitors can be associated 
with distinct transcriptional states, we sought to understand whether both of these states could be 
established from the same precursor cell.  At baseline, we found that immortalized primary 
human melanocytes expressed high levels of both MITF and its target genes, reminiscent of 
MITF-high/NF-κB-low melanoma cell lines.  Consistent with the aforementioned transcriptional 
class distinction in melanoma, expression of NF-κB-associated signatures and marker genes was 
low in these cells.  (Fig. 2.8A and 2.8B)  
In order to model the BRAFV600-mutant status of our cell line panels, we first introduced 
BRAFV600E into these melanocytes.  As expected, ectopic BRAFV600E expression augmented 
ERK phosphorylation (Fig. 2.8B).  Consistent with prior observations[36], introduction of 
BRAFV600E abrogated expression of MITF and its target genes at both the transcriptional (Fig. 
2.8A) and protein levels (Fig. 2.8B).  Interestingly, expression of BRAFV600E also induced NF-
κB pathway activation, as measured by NF-κB associated gene set expression (Fig. 2.8A), RelA 
phosphorylation (Fig. 2.8B), and expression of markers such as AXL and TPM1 (Fig. 2.8A, 
2.8B).  Thus, ectopic expression of BRAFV600E in melanocytes phenocopied the expression 
pattern of intrinsically resistant melanomas.  Comparable results were obtained even after 
prolonged (8-12 week) expression of BRAFV600E in melanocytes (Fig. 2.8C), suggesting that 
these phenotypic patterns are durable.  MEKDD similarly suppressed MITF and up-regulated 
AXL, whereas MAPK pathway inhibitors largely reversed these effects.  (Fig. 2.8A, 2.8B) These 
results suggest that aberrant MAPK pathway signaling is both necessary and sufficient for 
BRAFV600E to effect these transcriptional changes.  In addition, BRAFV600E-mediated induction 
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of AXL (though not loss of MITF) was partially antagonized by an IκBα super-repressor (Fig. 
2.9), suggesting that NF-κB activation induced by BRAFV600E contributes at least partially to 
expression of marker genes associated with the NF-κB-high class.  Altogether, these results 
suggest that, while melanocytes begin in an NF-κB-low/MITF-high state, the NF-κB-
high/MITF-low phenotype can be induced by gain of BRAFV600E.   
Although BRAFV600E can induce a NF-κB-high/MITF-low cell state in melanocytes in vitro 
([36], Fig. 2.8A-2.8C), most BRAFV600-mutant melanomas exhibit the opposite (i.e., MITF-
high/NF-κB-low) cell state both in vitro and in vivo.  Because MITF expression is a prominent 
feature of the low-NF-κB state, we hypothesized that concomitant MITF dysregulation might 
block or even reverse BRAFV600E-induced transition to the high-NF-κB state.  To test this, we 
ectopically expressed MITF in melanocytes simultaneously with either BRAFV600E or MEKDD.  
Indeed, expression of MITF blocked the ability of BRAFV600E or MEKDD to induce AXL 
expression (Fig. 2.8D), implying a blunted transition into the NF-κB-high transcriptional state.  
This effect was dependent on the ability of MITF to bind DNA, as a DNA binding-deficient 
mutant (MITF(R217Δ)) was unable to suppress AXL expression (Fig. 2.8D).  Consistent with 
this data, we found an enrichment of MITF amplification in MITF-high/NF-κB low melanoma 
cell lines relative to MITF-low/NF-κB-high lines (Fig. 2.8E).  In some cases, we also observed 
up-regulation of a gene set associated with cAMP signaling (Fig. 2.8E), which is known to 
induce MITF expression [103, 104].  These observations suggest that, even in the presence of 
BRAFV600E, MITF dysregulation can result in maintenance of a high-MITF/low-NF-κB state. 
Collectively, these data imply that both MITF-low/NF-κB-high and MITF-high/NF-κB-low 
cellular states can be established from the same precursor melanocyte through discrete genetic 
perturbations.  They also raise the possibility that a key determinant of transcriptional states 
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associated with resistance versus sensitivity is the balance between, on the one hand, BRAFV600E-
mediated MAPK activation and subsequent NF-κB induction, and, on the other, sustained MITF 
expression.   
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Figure 2.8. Establishment of two-class dichotomy in melanocytes.  
(a) Effects of aberrant MAPK pathway activation on whole-genome expression profiles.   
(b) Effects of aberrant MAPK pathway activation on markers of the MITF-high and NF-κB-
high classes; E, VTX11E (ERKi); P, PLX4720 (BRAFi); A, AZD6244 (MEKi), all overnight 
at 2 µM.   
(c) Effects of chronic BRAFV600E expression of markers of the MITF-high and NF-κB-high 
classes.  Experiments were performed in TICVA medium (+) or Ham’s F10 (-) as indicated.  
(d) Effect of MITF overexpression on MAPK pathway-induced expression changes.   
(e) Relationship between MITF expression levels and MITF amplification.   
32 
 
   
a 
g
e
n
e
s
 
s
ig
. 
1 2 3 4 1 2 1 2 replicates matching score 
SILV_GENE 
MLANA_GENE -0.340 
MITF_GENE -0.373 
-0.412 
TYRP1_GENE 
s
ig
. 
re
s
is
ta
n
c
e
 
m
a
rk
e
rs
 
melanocytes 
g
e
n
e
s
 
s
e
n
s
it
iv
it
y
 
m
a
rk
e
rs
 
-0.457 
AXL_GENE 0.872 
NRP1_GENE 0.871 
TIAN_TNF_NFKB 
HINATA_NFKB_FB 
0.880 
0.874 
SEKI_LPS 0.865 
Yokoyama_MITF -0.390 
Z score +2 -2 
b 
pERK 
ERK 
MLANA 
BRAF 
V5-MEK1
DD
 
Actin 
MITF 
L
a
c
Z
 
B
R
A
F
V
6
0
0
E
 
M
E
K
1
D
D
 
DMSO 
B
R
A
F
V
6
0
0
E
 
B
R
A
F
V
6
0
0
E
 
A E P 
B
R
A
F
V
6
0
0
E
 
AXL 
pRelA 
MAPKi: 
melanocytes c 
pERK 
ERK 
AXL 
BRAF 
Actin 
TPM1 
MITF 
pRelA 
TICVA − + − − 
D
M
S
O
 
D
M
S
O
 
D
M
S
O
 
R
A
F
-i
 
BRAF 
V600E 
WT 
melanocytes 
d 
L
a
c
Z
 
B
R
A
F
V
6
0
0
E
 
M
IT
F
 
M
E
K
1
D
D
 
B
R
A
F
V
6
0
0
E
 
M
E
K
1
D
D
 
+
M
IT
F
 
M
IT
F
R
2
1
7
Δ
 
B
R
A
F
V
6
0
0
E
 
M
E
K
1
D
D
 
+
M
IT
F
R
2
1
7
Δ
 
pERK 
ERK 
AXL 
BRAF 
Actin 
pRelA 
V5-MEK1
DD
 
MITF 
n.s. 
melanocytes 
e 22 BRAF
V600
-mutant melanoma cell lines 
MITF_GENE (index
) 
MLANA_GENE 0.922 
0.887 Yokoyama_MITF 
0.858 SILV_GENE 
0.664 TYRP1_GENE 
cAMP_UP 0.837 
MITF_amp 0.443 
matching  
score 
IG
R
.1
 
g
e
n
e
s
 
s
ig
. s
e
n
s
it
iv
it
y
 
m
a
rk
e
rs
 
cAMP 
signature 
MITF 
amplify. 
Z score +
2 
-
2 
M
Z
7
.m
e
l 
S
K
.M
E
L
.2
8
 
M
M
A
C
.S
F
 
C
3
2
 
U
A
C
C
.2
5
7
 
C
O
L
O
.6
7
9
 
G
.3
6
1
 
R
V
H
.4
2
1
 
C
O
L
O
.8
0
0
 
M
E
L
.H
O
 
H
T
.1
4
4
 
U
A
C
C
.6
2
 
M
1
4
 
A
1
0
1
D
 
A
2
0
5
8
 
IS
T
.M
E
L
1
 
S
K
.M
E
L
.2
4
 
A
3
7
5
 
W
M
.1
1
5
 
L
O
X
IM
V
I 
R
P
M
I.
7
9
5
1
 
Figure 2.8 (continued) 
33 
 
  
Figure 2.9. 
Effect of the IκBα super-repressor on MAPK pathway-mediated AXL induction. 
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4. Plasticity of two-class dichotomy in melanoma cell lines.   
Since MITF and NF-κB can influence the establishment of distinct cell states in melanocytes, we 
next sought to determine whether these factors could also regulate maintenance of these states in 
established melanoma cell lines.  Therefore, we hypothesized that induction of MITF expression 
might perturb MITF-low/NF-κB-high cells away from their NF-κB high state.  In NF-κB-
high/MITF-low cell lines, treatment with cAMP, forskolin, or alpha-melanocyte stimulating 
hormone (a key regulator of cAMP signaling in melanocytes [104]) induced CREB activity and 
MITF expression while downregulating markers associated with the NF-κB-high/resistant state 
(including AXL, NRP1, CDH13, and TPM1).  (Fig. 2.10A, 2.11) Similarly, ectopic expression 
of MITF antagonized expression of these markers regardless of MAPK pathway inhibitor 
treatment (Fig. 2.10B).   
Conversely, we hypothesized that induction of NF-κB would modulate a cell line from a 
sensitive, MITF-high state to a resistant, MITF-low state.  Consistent with prior work [105], we 
found that genetic or pharmacological perturbations that activate NF-κB (TNFα stimulus, or 
expression of IKBKB or TRAF2) also confer resistance to RAF, MEK, RAF+MEK, and ERK 
inhibition (Fig. 2.12A).  Although these stimuli robustly activate NF-κB, they do not rescue 
pERK following RAF inhibitor treatment (Fig. 2.12B).  Mechanistically, NF-κB activation 
appears to decrease apoptosis (as measured by Annexin V staining) and cell cycle arrest induced 
by PLX4720 (Fig. 2.12C)—effects consistent with the known role of NF-κB in suppressing 
apoptosis and driving cell cycle progression.  We further predicted that this NF-κB resistance 
phenotype would be accompanied by a change in transcriptional profile consistent with 
acquisition of the NF-κB-high/MITF-low state.  Indeed, following treatment of sensitive lines 
with TNFα (an NF-κB agonist), we observed diminished MITF expression and, in some cell 
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lines, induction of resistance markers including AXL (Fig. 2.10C, 2.13), thus linking TNFα-
mediated signaling to acquisition of markers of intrinsic resistance.  Blockade of NF-κB activity 
with the IκBα super-repressor abrogated these TNFα-mediated expression changes (Fig. 2.10C), 
confirming the necessity of NF-κB for this effect.   
Finally, because MAPK pathway hyperactivation can promote establishment of this high NF-
κB/MITF-low state in melanocytes, we wondered whether therapeutic MAPK pathway inhibition 
in BRAFV600-mutant melanomas would affect maintenance of this state.  To test this hypothesis, 
we cultured four MITF-high, MAPK pathway inhibitor-sensitive melanoma cell lines 
continuously in PLX4720 until a resistant population emerged (Fig. 2.14).  Interestingly, 
resistant clones showed diminished MITF expression (4/4 lines) and gain of AXL expression 
(2/4 lines, Fig. 2.10D).  These results suggest that in some contexts, MITF-high/NF-κB-low 
melanomas can transition towards an NF-κB-high/MITF-low state during acquisition of 
resistance.  These changes were observed even in clones that had also gained other known 
mechanisms of resistance (Fig. 2.10D, e.g., COT expression and p61 BRAF splice variant [90, 
92].  This finding implies that transition towards a NF-κB-high/MITF-low state in not mutually 
exclusive with acquisition of other known resistance effectors—an emerging theme in resistance 
to targeted therapeutics [106].  Thus, whereas the pre-treatment transcriptional state may 
influence intrinsic sensitivity to MAPK pathway inhibition, plasticity between states may also 
contribute to acquired resistance.  Cumulatively, these findings demonstrate that, even in 
melanoma cell lines, the transcriptional states associated with sensitivity and resistance remain 
plastic; moreover, maintenance of these states in cell lines can be perturbed by the same 
mediators that govern establishment of these states in melanocytes.   
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Figure 2.10. Plasticity of two-class dichotomy in melanoma cell lines.   
(a) Effect of cAMP, forskolin, or αMSH, in combination with IBMX, on expression of MITF 
and resistance markers.   
(b) Effect of MITF overexpression on resistance marker expression, in the presence or 
absence of PLX4720 (2 µM, overnight).   
(c) Effect of TNFα (25 ng/mL final), with or without concomitant IκBα super-repressor 
expression, on MITF and resistance markers.  
(d) Comparison of MITF and AXL expression in parental sensitive and cultured-to-resistant 
melanoma cell lines, in presence or absence of 2 2 µM PLX4720 (24 hrs).  PR1 and PR100 
denote independent derivations of a resistant subclone.  
(e) Model of two-class dichotomy in melanoma. 
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Figure 2.11. 
In intrinsically resistant melanoma lines, effect of forskolin, cAMP, and αMSH on expression 
of MITF, AXL, and other markers of the NF-κB-high/MITF-low state. 
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Figure 2.12: Perturbations activating the NF-κB pathway confer resistance to MAPK 
pathway inhibition. 
(a) Following expression of the indicated ORFs or stimulus with TNFα (25 ng/mL), GI50 
values were calculated for melanoma cells lines following 4d treatment with the indicated 
MAPK pathway inhibitors.  MEK1 is a negative control. 
(b) Following the indicated perturbations, cells were assessed for NF-κB pathway activation 
(as measured by pRelA) and for MAPK pathway activation (as measured by pERK), in the 
presence or absence of PLX4720.  CRAF is a positive control for MAPK pathway re-
activation in the presence of PLX4720; MEK1 is a negative control.   
(c) Effects of TNFα stimulus on PLX4720-mediated induction of apoptosis (as measured by 
annexin V (+)/PI (−) staining) and cell cycle arrest.  Experiments were conducted in A375 
cells. 
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Figure 2.13. 
Effect of TNFα (25 ng/mL for indicated time) on expression MITF, MITF target genes, and 
markers associated with the high-NF-κB/low-MITF class. 
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Figure 2.14. 
Drug sensitivity characterization of parental and cultured-to-resistant melanoma cell lines.   
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Discussion and future directions 
Cumulatively, the work in this chapter has characterized two cellular states in BRAFV600-mutant 
melanoma: one characterized by high MITF expression that is sensitive to MAPK pathway 
inhibition, and another that exhibits low MITF expression, high NF-κB activity, and intrinsic 
resistance to MAPK pathway inhibition.  While this type of transcriptional class distinction has 
long been recognized in melanoma [101], its possible association with differential response to 
vemurafenib or dabrafenib/trametinib in BRAFV600-mutant melanoma is novel.  The initiation of 
these states in primary melanocytes can be controlled by the relative balance of aberrant MAPK 
activation (leading to NF-κB activation) and MITF levels.  In melanoma cell lines, these cell 
states appear to remain plastic in response to perturbations of NF-κB and MITF.   
Origin of the low-MITF, high-NF-κB state 
These observations raise several fundamental questions worthy of future investigation.  First: 
how does introduction of BRAFV600E into melanocytes induce the low-MITF, high-NF-κB state? 
We have elucidated certain mechanistic observations that may be pertinent to this process.  
BRAFV600E, as a constitutively activating mutation, induces aberrant downstream MAPK 
pathway flux.  This altered MAPK flux (rather than some other intrinsic property of mutant 
BRAF) appears crucial for induction of the low-MITF, high-NF-κB state, because the same 
phenotype arises when constitutively active MEK (MEKDD) is expressed, and because this 
transition is attenuated by concomitant treatment with MAPK pathway inhibitors.   
One important question is whether the loss of MITF and induction of NF-κB/AXL that we and 
others[36]  have observed following ectopic BRAFV600E expression are artifacts of supra-
physiological MAPK pathway flux in this in vitro melanocyte model.  Conceivably, the natural 
acquisition of BRAFV600E that occurs in patients might often drive less flux through the MAPK 
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pathway, permitting maintenance of a MITF-high, NF-κB-low expression phenotype.  While we 
cannot fully exclude this possibility, several lines of evidence suggest that MAPK pathway flux 
in our experimental system is not abnormally high.  First, melanocytes expressing BRAFV600E 
over a chronic timecourse (8-12 weeks) did not express higher levels of BRAF than BRAFWT 
parental melanocytes, yet maintained low MITF and robust AXL expression.  This observation 
suggests that even physiological levels of BRAF expression can induce the observed expression 
changes.  Second, melanocytes expressing BRAFV600E over an acute timecourse (3-5 days), 
although overexpressing BRAF relative to parental cells, displayed pERK levels only moderately 
above those of parental melanocytes.  Thus, at least as measured by pERK, MAPK flux 
following acute BRAFV600E expression appears to be elevated but not grossly supra-
physiological.  Moreover, at the level of either pERK or pFRA1, we observe no difference in 
MAPK pathway activation between sensitive and resistant melanomas, arguing that MAPK 
pathway flux is not a distinguishing feature between these two classes.  Nonetheless, to query 
more definitively the possibility that differential MAPK pathway flux might contribute to the 
acquisition of these dichotomous transcriptional states, future investigations could use 
approaches affording more precise control over BRAFV600E expression levels (e.g., inducible 
lentiviral systems, or TALEN-mediated genome editing).   
Our work shows that, in melanocytes, aberrant MAPK pathway activation (by BRAFV600E or 
MEKDD) can induce NF-κB pathway activity (as measured by pRelA and gene sets marking NF-
κB activation).  Furthermore, we have demonstrated in melanoma cell lines that NF-κB 
activation (e.g., by TNFα) can cause loss of MITF expression.  (Abrogation of this effect with 
the IκBα super-repressor confirms that it requires NF-κB activation.) These findings raise the 
question of whether NF-κB activation is responsible for loss of MITF expression following 
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acquisition of BRAFV600E in melanocytes.  In fact, our data argue that, following BRAFV600E 
expression, NF-κB activation is not required for loss of MITF, as blockade of the NF-κB 
pathway with the IκBα super-repressor did not prevent BRAFV600E-mediated loss of MITF 
expression.  This conclusion is consistent with prior evidence that direct phosphorylation of 
MITF by ERK leads to its proteasomal degradation [107, 108].  Thus, while it is clear that 
MAPK pathway hyperactivation can cause both activation of NF-κB and loss of MITF 
expression, it appears that MAPK pathway flux itself rather than subsequent NF-κB induction is 
the critical factor controlling MITF loss.   
The relationship between BRAFV600E and gain of NF-κB activity/resistant state markers also 
deserves further elucidation.  Of note, one such marker, AXL, has been previously characterized 
as an effector of acquired resistance to MAPK pathway inhibition in BRAF-mutant melanoma.  
In Chapter 3, we investigate the question of whether AXL, in addition to marking the NF-κB-
high state, might also contribute to the phenotype of intrinsic resistance.  In melanocytes, 
BRAFV600E induces NF-κB activation and gain of resistance markers (e.g., AXL) associated with 
the high NF-κB state.  A relevant question is therefore whether NF-κB activation controls 
acquisition of these resistance markers.  Indeed, NF-κB activity is sufficient to induce AXL, as 
we have shown that NF-κB activation (by TNFα) can induce AXL expression in high-MITF cell 
lines.  Moreover, in melanocytes, co-expression of BRAFV600E with the IκBα super-repressor 
impaired BRAFV600E-mediated induction of AXL expression, implying that NF-κB 
transcriptional activity is necessary for maximum AXL induction.  However, BRAFV600E induced 
some AXL expression even in the context of the IκBα super-repressor, suggesting that other, as 
yet unknown, pathways downstream of MAPK pathway hyperactivation also contribute to the 
induction of markers of the resistant state.  Identifying these other signals transduced secondary 
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to BRAFV600E is a critical area for future work, since we have shown that induction of this state is 
a critical determinant of subsequent MAPK pathway inhibitor sensitivity.   
Origin of the high-MITF, low-NF-κB state 
Given that introduction of BRAFV600E into melanocytes can lead to loss of MITF expression, it 
may seem surprising that the majority of BRAFV600E melanomas retain MITF expression and low 
levels of NF-κB activity.  At least two potential explanations for this observation may be 
envisioned.  First, it is possible that the majority of BRAFV600E melanomas adaptively dampen 
MAPK pathway flux following acquisition of BRAFV600E (e.g., by DUSP upregulation or other 
feedback regulatory mechanisms, [109]).  Under this model, melanomas able to moderate the 
aberrant MAPK pathway flux induced by BRAFV600E might maintain MITF despite acquisition 
of this mutation.  In contrast, those melanomas less able to do so (e.g., because of concomitant 
loss of negative feedback regulation) would be more likely to lose MITF expression, thus 
entering the low-MITF/high-NF-κB state.  As discussed above, we have to this point not detected 
any steady-state differences in MAPK pathway flux between the high-MITF and high-NF-κB 
classes.  Nonetheless, explanation remains possible. 
An alternative possibility is that many melanocytes may sustain concomitant alterations that 
preserve an MITF-high/NF-κB-low cellular state despite aberrant MAPK pathway flux following 
gain of BRAFV600E.  Indeed, our data suggests that dysregulation of MITF can impair 
BRAFV600E-mediated induction of the high-NF-κB state in melanocytes and maintenance of this 
state in intrinsically resistant cell lines.  Moreover, MITF amplification was enriched in the high-
MITF cell lines relative to the high-NF-κB cell lines, suggesting that this genomic alteration may 
explain how some melanomas maintain MITF following acquisition of BRAFV600E.  However, 
MITF amplification is unlikely to be the only—or even the predominant—mechanism by which 
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cells can maintain MITF following introduction of BRAFV600E, as is implied by the fact that most 
high-MITF BRAFV600-mutant cell lines do not harbor MITF amplification.  Further 
understanding of how BRAFV600-mutant cells maintain MITF expression will be a fruitful area of 
investigation in light of the importance of MITF expression in determining MAPK pathway 
inhibitor sensitivity vs. resistance. 
While we do not have a complete mechanistic description of why MITF expression marks 
MAPK pathway dependence, this observation is globally consistent with prior work.  In 
melanocytes, MITF is known to be phosphorylated by the MAPK pathway.  While this 
phosphorylation does decrease MITF protein stability (as previously discussed), it also enhances 
MITF transcriptional activity.[107] Although BRAFV600-mutant melanoma cells are a notably 
different cellular context than BRAFWT melanocytes, it appears plausible that MITF marks 
MAPK pathway inhibitor sensitivity because, in these melanoma cell lines, MITF requires 
continued MAPK input in order to continue to exert its essential pro-growth, pro-survival 
oncogenic transcriptional functions.   
Mechanistic characterization of the low-MITF, high-NF-κB state 
Questions also remain about the high-NF-κB state.  For example, if BRAFV600E induces this state 
in melanocytes, how is it that melanoma cells displaying a similar transcriptional profile 
demonstrate indifference to MAPK pathway inhibition? In several resistant lines, we have 
seemingly ruled out the trivial explanation of that resistance is due to inadequate pathway 
inhibition, as treatment with MAPK pathway inhibitors produces comparable suppression of 
pERK and pFRA1 in both sensitive and resistant lines.  While it remains possible that other 
markers of MAPK pathway flux would show less inhibition in the resistant lines, data obtained 
to this point suggest that these lines are fundamentally less dependent on MAPK pathway 
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activation.  In Chapters 3 and 4 we present our efforts to query the role of AXL and COT, 
respectively, as mechanisms of intrinsic resistance.  Even in light of these studies, we still lack a 
comprehensive mechanistic understanding of why cells in this state are resistant to MAPK 
pathway inhibitors.   
In addition to understanding how MITF-low, NF-κB-high melanomas are resistant to MAPK 
pathway inhibition, another question involves the effectors of oncogenic transformation operant 
in this setting.  BRAFV600E and MITF amplification are typically considered cooperating 
oncogenic events.  Although BRAFV600E is a melanoma oncogene, it is not individually sufficient 
for high-efficiency transformation of melanocytes.  Rather, it requires cooperation from 
amplification/overexpression of MITF.[36]  Since the high-NF-κB melanomas have BRAFV600 
mutations but lack MITF, did additional oncogenic alterations (copy number changes, mutations, 
etc.) contribute to transformation of these cells? To address this question, one could extend the 
current analyses to query, in an unbiased fashion, what other features—whether mutation, copy 
number changes, or enrichments of individual genes or signatures—are differentially associated 
with the intrinsically resistant subtype.  Alternatively, one could pursue focused studies to 
determine whether specific NF-κB effectors (e.g., those induced by BRAFV600E in high-NF-
κB/low-MITF lines) can cooperate with BRAFV600E to transform melanocytes.  Together, such 
studies could provide a comprehensive characterization of this alternative cellular state in 
melanoma, and could nominate additional factors responsible for the initiation and/or 
maintenance of this state. 
Last, it is noteworthy that the transcriptional state observed in the majority of BRAFV600-mutant 
melanomas corresponds to that observed in basal melanocytes (i.e., high MITF and low NF-κB) 
Therefore, is it possible that the alternative, MITF-low/NF-κB-high state represents an 
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alternative cellular fate corresponding to a previous developmental state in the natural history of 
melanocytes or the neural crest? Although highly speculative, this possibility could shed 
additional light on the transcriptional programs elaborated by this subclass of melanomas. 
Therapeutic possibilities in high-NF-κB lines 
If most low-MITF/high-NF-κB lines exhibit reduced dependence on MAPK pathway signaling, 
what treatment strategies might be pursued to kill these melanomas? Here, two conceptual 
possibilities may be envisioned.  On the one hand, the intrinsically resistant lines might in fact 
retain an underlying dependency on MAPK pathway activation, but that dependency is masked 
by the expression of one or several resistance effectors.  Alternatively, these intrinsically 
resistant cell lines, despite the presence of BRAFV600E, might have no underlying dependency on 
the MAPK pathway. 
In the first case, an interesting strategy could involve searching for perturbations that would 
render the high NF-κB lines sensitive to MAPK pathway inhibitors.  Although not yet 
comprehensively investigated, this approach has so far proven challenging, as perturbation of 
individual candidate resistance effectors has not sensitized these lines to MAPK pathway 
inhibition (cf. COT perturbation in Ch.  3 and AXL perturbation in Ch.  4).  This question could 
also be explored systematically using genome-scale shRNA screens in the presence vs. absence 
of MAPK pathway inhibitors in one or more intrinsically resistant lines.  Of course, it is 
conceivable that the intrinsic resistance phenotype is multifactorial, meaning that perturbation of 
single effectors may not exhaustively identify the relevant effectors. 
A second approach, particularly appropriate if these lines lack an underlying MAPK pathway 
dependency, would be to identify novel vulnerabilities through pharmacologic or genetic 
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screens.  Pharmacologically, small molecule screens could identify for novel vulnerabilities in 
the intrinsically resistant lines.  Aside from MAPK pathway inhibitors, we did not note any 
differential sensitivity or resistance between the two classes of melanoma in the CCLE data set; 
however, only 26 compounds are currently available for this collection.  It is possible, however, 
that generation of a broader pharmacological profiling dataset across these cell lines (as currently 
being undertaken by the CTD2 effort at the Broad Institute) might reveal vulnerabilities specific 
to this class.  A complementary approach would be to use shRNA screening data to search for 
genetic vulnerabilities either shared across all melanomas (regardless of MITF expression) or 
specific to the low-MITF, high-NF-κB subclass.  Indeed, the former approach is detailed in 
Chapter 5; the latter is planned as part of ongoing systematic shRNA screening efforts at the 
Broad Institute.  Finally, using the computational discovery efforts outline above to identify 
novel molecular features of the intrinsically resistant melanomas, we may be able to nominate 
novel candidate dependencies within this subclass. 
Conclusion 
Together, this work has identified a cell state dichotomy in melanoma as a novel determinant of 
sensitivity versus resistance to MAPK pathway inhibition.  The origin of these states in 
melanocytes, as well their maintenance in melanoma cell lines, appears to be governed by the 
balance between MITF and BRAFV600E-induced NF-κB.  Although these studies have provided 
substantial insight, they have also laid the foundation for future questions regarding the 
mechanistic origin and potential vulnerabilities of these states.  These and other questions will 
provide many fruitful areas of investigation around the starting point described in this chapter. 
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Methods 
Constructs 
MEK1, MITF-M, and LacZ were from The RNAi Consortium (Broad Institute).  All lentiviral 
ORF expression constructs were in vectors pLX304-Blast-V5 or pLX980-Blast-V5.  The 
retroviral IκBα super-repressor construct has been previously published [61, 110] and was a kind 
gift from David Barbie and Jesse Boehm. 
Primary melanocytes 
Primary melanocytes were grown in TICVA medium (Ham’s F-10 (Cellgro), 7% FBS, 1% 
penicillin/streptomycin, 2 mM glutamine (Cellgro), 100 μM IBMX, 50 ng ml−1 TPA (12-O-
tetradecanoyl-phorbol-13-acetate), 1 mM 3′,5′-cyclic AMP dibutyrate (dbcAMP; Sigma) and 
1 µM sodium vanadate).  Following lentiviral introduction of BRAFV600E, cells were switched to 
Ham’s F10 + 10% FBS.   
Melanocyte infections 
Following infection, melanocytes chronically expressing BRAFV600E were selected for by 
survival in Ham’s + 10% FBS (without supplements) as BRAFV600E permits survival in the 
absence of TICVA supplements.   
Cell culture 
All cells were maintained in medium supplemented with 10% FBS (unless otherwise indicated) 
and 1% penicillin/streptomycin.  The following cell lines were maintained in RPMI-1640: A375, 
Colo679, RVH421, Skmel5, Skmel19, Skmel28, UACC62, WM983B, WM793, LOXIMVI, and 
all short-term cultures.  DMEM: WM88, WM266.4, G361, A2058, Hs294T.  MEM: RPMI7951.  
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DMEM with 15% FBS: IGR39.  All cell lines were obtained from in-lab stocks, from ATCC, or 
from Biological Samples Platform (Broad Institute). 
Cultured-to-resistance lines 
Colo679, G361, and Skmel28 were serially passaged in PLX4720 until resistance clones 
emerged.  For Skmel28, two separate derivations were performed.   
GI50 determination 
For drug sensitivity determinations, lines were seeded in 96w format at the following densities: 
Cell lines: A375, 3000; Colo679, 8500; Skmel19, 12000; Skmel28, 2000; A2058, 3500; Hs294T, 
6000; WM793, 6000; RPMI7951, 4250; IGR39, 3000. 
Short-term cultures: Wm1745, 8500; Wm1852, 8500; Wm1930, 8500; Wm1862, 12000; 
WM1942, 16000; WM1976, 8500; WM3215, 6000; WM3482, 7250; Wm3727, 12000; 
Wm451Lu, 4500. 
The day after plating, if applicable, recombinant human TNFα (CST 8902SC) was added to a 
final concentration of 25 ng/mL.  Cells were then drugged with serial dilutions of indicated 
inhibitors in medium plus DMSO to give final concentrations ranging from 100 µM to 31.62 nM 
(PLX4720 and VTX11E) or 31.62 µM to 10 nM (AZD6244), in half-log increments.  For 
combined PLX4720 and AZD6244 treatment, a linear combination of doses was used, starting at 
100 µM PLX4720 + 31.62 µM AZD6244.  After 4 days of drug treatment, cellular viability was 
read using CellTiter-Glo and compared to DMSO wells.  GI50 calculations were performed in 
GraphPad Prism; for AZD6244, floor value was set to 0. 
Steady-state protein expression 
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For lysate harvesting, lines were plated in 10 cm dishes at the following densities, to reach 
equivalent confluence at harvest, and lysed 5 days after plating. 
Cell lines: A375, 7.4e5; Colo679, 2.1e6; RVH421, 1e6; Skmel5, 1.5e6; Skmel19, 3e6; Skmel28, 
7e5; UACC62, 1.5e6; WM983B, 1.2e6; G361, 2.1e6; Wm88, 1.5e6; Wm266.4, 1.1e6; A2058, 
8.61e5; Hs294T, 1.5e6; Wm793, 1.5e6; RPMI7951, 1.1e6; IGR39, 7.4e5; LOXIMVI, 1.3e6. 
Short-term cultures: WM1745, 2.1e6; Wm1852, 1.6e6; Wm1930, 2.5e6; WM1862, 3e6; 
Wm1942, 3.5e6; Wm1976, 2.1e6; Wm3215, 1.5e6; WM3482, 2.1e6; Wm3727, 3e6; Wm451Lu, 
1.1e6. 
MAPK pathway inhibitor treatment 
Cells were seeded in 6-well format at the following densities: RVH421, 1.8e5; Skmel19, 5e5; 
G361, 3.6e5; A2058, 1.5e5; Hs294T, 2.5e5; WM793, 2.5e5; RPMI7951, 1.8e5; IGR39, 1.25e5.   
Forskolin timecourse 
Cells were seeded in 12-well plates at the following densities: Hs294T, 1e5; RPMI7951, 7.2e4; 
IGR39, 5.1e4.  The following day, cells were stimulated at the 4 day timepoint with IBMX (100 
µM final) plus either forskolin (10 µM final), db-cAMP (1 mM final), or αMSH (1 µM final).  
Subsequent timepoints were stimulated as indicated.   
Ectopic MITF expression 
Cells were seeded in 12-well plates at the following densities: A2058, 6.3e4; Hs294T, 1.1e5; 
Wm793, 1.1e5; LOXIMVI, 1.4e5.  The following day, polybrene was added to 4 µg/mL final, 
100 µL of the indicated ORF lentivirus was added, and cells were infected 60 minutes at 2250 
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rpm (1178 x g) at 30 °C.  Medium was changed immediately following infection Four days later, 
medium was changed to fresh medium plus DMSO or 2 µM PLX4720 as indicated. 
TNFα timecourse 
Cells were seeded in 12-well plates at 7.5e4 cpw, except Skmel19 at 1e5 cpw and treated with 
TNFα at 25 ng/mL final for the indicated timepoints. 
TNFα timecourse with IκBα super-repressor 
Cells were seeded in 12w format at 4.1e4 (Skmel19) and 8.1e4 (WM266.4) cpw.  The next day, 
cells were changed to medium plus 4 µg/mL polybrene, then infected with 375 µL retrovirus 
(60’ spin, 2250 rpm (1178 x g), 30 °C).  The following morning, cells were changed to fresh 
medium.  In the afternoon, cells were changed again to medium plus 4 µg/mL polybrene, 
infected again with 375 µL retrovirus.  That evening, infection was repeated.  The next day, 
medium was changed to fresh medium plus 1 µg/mL final puromycin, and cells were stimulated 
for the 6d TNFα timepoint (25 ng/mL final).  Subsequent timepoints were stimulated as 
indicated.   
Lysate harvesting 
Cells were harvested by washing 1x in PBS, applying sufficient lysis buffer to cover the well (~ 
40 uL for 12w plate, ~100 uL for 6w plate, ~250 µL for 10 cm plate), and removing lysis buffer.  
Plates were not scraped and lysates were not pelleted.  Cells were lysed in 1% NP40 buffer 
(150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF and 1% NP-40), containing 
2x EDTA-free protease inhibitor cocktail (Roche) and 1x phosphatase inhibitors I and II (EMD).  
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Lysates were quantitated by BCA, normalized, and denatured by boiling in sample buffer plus 20 
mM DTT. 
Western Blotting 
Transfers were on iBlot nitrocellulose membrane using setting P0.  Membranes were blocked 1 
hour at room temperature in LiCor blocking buffer.  Primary antibodies (1:1000 dilution unless 
otherwise indicated) were incubated overnight at 4°C in LiCor blocking buffer plus 0.1% Tween-
20.  Secondary antibodies (1:10,000 dilution, LiCor) were incubated at room temperature for 90 
minutes in LiCor blocking buffer plus 0.1% Tween-20 and 0.1% SDS.  Imaging was on a LiCor 
Odyssey infrared imager. 
Primary antibodies were as follows (CST = Cell Signaling Technology, SCBT = Santa Cruz 
Biotechnology): 
AXL (C44G1, CST 4566; 6C8, Sigma WH0000558M1); MITF (C5, NeoMarkers MS771P, 
1:400); SILV (A46.  Sigma SAB4100050, 1:500); TYRP1 (G17, SCBT sc-10443, 1:200); 
MLANA (A103, SCBT, sc-20032, 1:500); pRelA (S536, 93H1, CST 3033); tRelA (L8F6, CST 
6956); CDH13 (Sigma SAB1405597, 1:200); NRP1 (D62C6, CST 3725); TPM1 (D12H4, CST 
3910); Cofilin (D3F9, CST 5175, 1:20,000); pERK (T202/Y204, D13.14.4E, CST 4370); tERK 
(L34F12, CST 4696); pFRA1 (S265, D22B1, CST5841); V5 (Invitrogen R960-25) ; BRAF (13, 
BD Biosciences 612375); pCREB (S133, 87G3, CST 9198); IκBα (L35A5, CST 4814); COT 
(N17, SCBT sc-1717); pS6 (S235/S236, D57.2.2E, CST 4858); tS6 (54D2, CST 2317) 
Gene expression and pharmacological analyses 
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Gene expression (RMA normalized using ENTREZG v15 CDF), drug sensitivity (IC50 values), 
and genotyping data for BRAFV600-mutant melanoma cell lines were from the Cancer Cell Line 
Encyclopedia (CCLE).[100]  Pearson correlation coefficients (r) were computed between 
PLX4720 GI50 values and gene expression value.  For Fig. 2.8E, gene expression, genotyping, 
and copy number data were from the Wellcome Trust/Sanger COSMIC Cell Lines Project.[111]  
Gene expression and genotyping data for melanoma short-term cultures (Fig. 2.3A) was from 
Lin et al. [112] and was collapsed to maximum prove value per gene using GSEA Desktop.  
Genotyping and gene expression data for melanoma tumors in Fig. 2.1D was from The Cancer 
Genome Atlas.   
Analysis of CCLE data 
The single-sample GSEA enrichment scores used in Figs. 2.1B, 2.1D, 2.3A, 2.8A, and 2.8E 
were obtained as previously described [68, 113].  Briefly, for every gene expression sample 
profile, the values were first rank-normalized and sorted and then a single-sample enrichment 
score for each gene set was computed on the basis of the integrated difference between the 
empirical cumulative distribution functions of the genes in the gene set versus the rest.  This 
procedure is similar to the computation of standard GSEA but is based on absolute rather than 
differential expression.  Published details of this method and other applications are available. 
[114-116]  The full names of gene sets referenced in the text and figures are 
hinata_nfkb_targets_fibroblast_up ("Hinata_NFKB_FB "), and 
seki_inflammatory_response_lps_up ("Seki_LPS"), and tian_tnf_signaling_via_nfkb 
(“Tian_TNF_NFKB”).  The “Yokoyama_MITF” signature was derived from Yokoyama et al.  
[11], Supplementary Tables 5 and 6B (only genes induced/repressed by overexpression of wild-
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type MITF were included).  Matching scores between index variables other variable were 
obtained by a normalized and rescaled mutual information estimate.   
Briefly, we consider the differential mutual information between two continuous vectors x 
(target, for example, PLX4720 resistance) and y (feature, for example, an NF-κB gene set): I(x, 
y) = ∫∫P(x, y) log2(P(x, y)/(P(x)P(y)))dxdy and estimate this quantity with a kernel-density 
estimate of the joint distribution P(x,y).  The discrete data are smoothed with a Gaussian kernel, 
with width determined by a cross-validation bandwidth estimation at each data point (xi, yi), and 
P(x,y) is found by summing overall densities over a discrete grid (100 × 100).  The resulting 
estimate of differential mutual information, I(x,y) is then normalized (73, 74) by the joint 
entropy H(x,y) = ∫∫P(x,y) log2P(x,y)dxdy, to obtain U(x,y) = I(x,y)/H(x,y).  Finally, the matching 
score is obtained by rescaling U(x, y) using the normalized mutual information of x (the target) 
with itself and adding a “direction” (±) according to the Pearson correlation ρ(x, y): S(x, y) = 
sign(ρ (x, y))U(x, y)/U(x, x).  A perfect match (antimatch) corresponds to a score of +1(−1) and 
a random match to 0.  This matching score S(x, y) has advantages over other metrics including 
increased sensitivity to nonlinear associations and wider dynamic range at the top of the 
matching scale. 
ICC 
Five days after seeding in 15 cm plates, cells were rinsed once in cold PBS, scraped in PBS on 
ice, and pelleted at 1000 x g.  Pellets were subsequently formalin-fixed, paraffin-embedded, and 
processed as below. 
Immunohistochemistry 
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4 µM sections of formalin-fixed, paraffin-embedded specimens were heated at 60°C, 
deparaffinized in xylene, and hydrated in a series of ethanol dilutions.  Epitope retrieval was by 
microwaving (5 min full power, 15 min reduced power) in 10 mM Tris-EDTA buffer pH 9.0.  
Slides were blocked 10 minutes in 3% BSA in TBST (Tris pH 7.6 + 0.05% Tween-20).  Primary 
antibodies were as follows: MITF, 1:100 in 3% BSA in TBST, clone D5 (Dako M3621); AXL, 
1:100 in 3% BSA in TBST, clone C89E7 (Cell Signaling Technologies 8661).  Slides underwent 
10 min peroxidase block in 3% H2O2.  Secondary antibodies were: Goat anti-mouse IgG-HRP 
(BioRad 170-6516, 1:200 in 3% BSA in TBST; Dako EnVision anti-rabbit (K4003) ready-to-
use.  Slides were developed with DAB+ (Dako K3468) for 10 min, and counterstained 1 min 
with hematoxylin (Vector H-3401), prior to dehydration and mounting.  Slides were scored for 
intensity and distribution of AXL and MITF by a dermatopathologist blinded to clinical 
outcome.   
Analysis of cell cycle and apoptosis 
Cells were seeded into 10-cm dishes on day 0; treated as indicated with PLX4720 (1 mM), TNFα 
(25 ng/ml), or vehicle on day 1; and analyzed on day 3.  For analysis of cell cycle distributions, 
cells were fixed with 80% ethanol in water and stained with propidium iodide (PI) (50 mg/ml; 
BD Pharmingen) containing ribonuclease A (0.1 mg/ml) and 0.05% Triton X-100.  For the 
analysis of annexin V staining, cells were suspended in annexin V binding buffer (10 mM Hepes, 
140 mM NaCl, and 2.5 mM CaCl2, pH 7.4) containing annexin V–APC (allophycocyanin) (BD 
Pharmingen) and PI (50 mg/ml).  For both analyses, a minimum of 50,000 events were counted 
per sample.  Cell cycle data were analyzed with ModFit software.  Annexin V staining was 
analyzed with FlowJo software, with annexin V–positive cells defined as those exhibiting 
annexin V staining intensities exceeding 99.9% of cells in a PI-only control sample. 
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CHAPTER 3.  PERTURBING INTRINSIC MAPK PATHWAY INHIBITOR RESISTANCE:  
INVESTIGATING AXL AS A CANDIDATE MECHANISM  
Abstract 
In previous work, we characterized a gene expression signature associated with intrinsic 
resistance to MAPK pathway inhibitors in BRAFV600-mutant melanoma.  We further sought to 
understand whether any genes within this resistance signature, in addition to being markers of 
resistance, were also required for maintenance of intrinsic resistance.  To nominate such 
candidate effectors of intrinsic resistance, we intersected our resistance marker gene signature 
with a validated, near-genome scale list of ORFs sufficient to confer MAPK inhibitor resistance 
in BRAFV600-mutant melanoma.  Only one gene was present in both lists: the receptor tyrosine 
kinase AXL.  AXL was sufficient to confer resistance to inhibition of RAF and MEK (singly or 
in combination), although cells generally remained sensitive to ERK inhibition.  Nonetheless, 
shRNA knockdown of AXL, and small molecule inhibition of AXL, did not alter MAPK 
pathway signaling at baseline or following RAF inhibitor treatment, nor did these perturbations 
reproducibly sensitize intrinsically resistant cells to RAF inhibition.  Thus, while AXL is both a 
marker of intrinsic resistance and sufficient to confer acquired resistance, it is not required for 
maintenance of the intrinsically resistant state.  Nonetheless, these findings suggest that the 
systematic intersection of gene expression data and the results of genome-scale functional 
screens may nominate high-priority candidate mediators of drug-resistance phenotypes.   
Attributions 
All experiments and analyses were performed by David Konieczkowski except as follows: 
ORF screens described in Fig. 3.1 were performed by Cory Johannessen. 
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Introduction 
Background 
In the previous chapter, we used gene expression and pharmacologic data to distinguish 
BRAFV600-mutant melanoma into two classes: one, with high MITF expression, that was 
sensitive to MAPK pathway inhibition, and one with low MITF expression but high NF-κB 
activity and expression of other marker genes, that was resistant to MAPK pathway inhibition.  
In light of the significant expression differences between the MAPK pathway inhibitor sensitive 
and MAPK pathway inhibitor resistant classes, we sought to understand which if any of the 
genes overexpressed in the high-NF-κB class might contribute to the phenotype of intrinsic 
resistance. 
A systematic approach to nominating candidate resistance effectors 
In answering this question, we sought to develop an unbiased approach to identifying candidate 
mediators of intrinsic resistance to targeted therapeutics.  We reasoned that such putative 
resistance mediators might be both (1) overexpressed in intrinsically resistant relative to sensitive 
cell lines, and (2) individually sufficient to alter drug sensitivity.  For a given cancer lineage, 
genetic background, and targeted therapeutic intervention (e.g., MAPK pathway inhibition in 
BRAFV600-mutant melanoma), such an approach would require two datasets: (1) basal gene 
expression and pharmacologic sensitivity profiling across a panel of intrinsically sensitive and 
resistant lines and (2) functional genomic screening data for genes able to modify drug 
sensitivity/resistance phenotypes.  While expression profiling can identify genes associated with 
intrinsic resistance or sensitivity, functional screening can identify which if any of those 
candidates are necessary or sufficient to effect the phenotype of interest.  The intersection of 
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these datasets, therefore, would nominate high-priority candidate mediators of intrinsic 
resistance. 
 
Results 
1. Intersection of ORF screens and expression profiles identify AXL as a candidate effector 
of intrinsic MAPK pathway inhibitor resistance.   
To comprehensively query what potential effectors of resistance were differentially expressed in 
BRAFV600-mutant melanomas intrinsically resistant to MAPK pathway inhibition, we used two 
data sources.  First, building on prior kinome-scale screening efforts to identify mediators of 
MAPK pathway inhibitor resistance [92], our lab has recently completed a near-genome-scale 
screen for human open reading frames (ORFs) sufficient to confer resistance to MAPK pathway 
inhibition in BRAFV600-mutant melanoma (C.  Johannessen, unpublished).  This screen 
encompasses ~13,000 ORFs; although not fully comprehensive, it provides a broad survey of 
effectors sufficient to confer MAPK pathway inhibitor resistance in melanoma. 
Second, as a comprehensive query of single genes whose expression was associated with 
intrinsic resistance, we used the Cancer Cell Line Encyclopedia dataset, as described in Chapter 
2.  For this analysis, we considered a panel of 29 BRAFV600-mutant melanoma cell lines for 
which both gene expression profiles and pharmacological sensitivity data was available.  We 
calculated the correlation coefficient (r) between the expression levels of each gene and the 
measured PLX4720 GI50 concentration across the cell line panel.  As a result, genes with higher 
expression in lines intrinsically resistant to PLX4720 had positive correlation coefficients; genes 
with lower expression in intrinsically resistant lines had negative correlation coefficients.   
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Intersecting these two data sources (Fig. 3.1) yielded a total of 11,334 ORFs that could be 
subjected to our integrated analysis (e.g., they contained both ORF screening results and gene 
expression profiling annotation across the panel).  In secondary functional assays performed in 
the Garraway lab, 107/11334 ORFs were validated to confer MAPK pathway inhibitor resistance 
with a z score > 4.0.  Conversely, 77/11334 tested genes displayed strong (r>0.6) correlation 
with PLX4720 GI50, meaning that they were overexpressed in PLX4720 resistant lines relative to 
sensitive lines.  Intersecting those lists, we found that only one gene, the receptor tyrosine kinase 
AXL, was common to both categories.  This finding led us to hypothesize that AXL might be an 
effector of innate resistance to MAPK pathway inhibitors in BRAFV600-mutant melanoma cells. 
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Figure 3.1: Intersection of ORF screens and expression profiles identify AXL as a 
candidate effector of intrinsic MAPK pathway inhibitor resistance. 
Left: 12,912 human ORFs were screened in A375 for ability to confer resistance to MAPK 
pathway inhibition.  107 ORFs subsequently validated with z score >4.0. 
Right: Expression of 18,988 genes was profiled in the Cancer Cell Line Encyclopedia across 
a collection of BRAF_V600-mutant melanoma cell lines for correlation between gene 
expression and intrinsic MAPK pathway inhibitor resistance.  77 genes were correlated with 
r>0.6. 
Bottom: Of the 107 candidate resistance ORFs and 77 genes associated with intrinsic 
resistance, only one, AXL, was present in both lists.   
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2. Overexpression of AXL confers resistance to RAF, MEK, and RAF+MEK, but not ERK, 
inhibition 
Next, we validated the ability of AXL to confer resistance to a spectrum of MAPK pathway 
inhibitors.  (Expression of AXL in the resistant class was described in the previous chapter.) We 
lentivirally expressed AXL in three cell lines (A375, Skmel28, UACC62) and treated them with 
inhibitors of RAF (PLX4720, 2 µM), MEK (AZD6244, 200 nM), RAF and MEK in 
combination, or ERK (VTX11E, 2 µM).  Growth was then assessed after 4 days drug treatment.  
MEK1 was used as a negative control; RAF1 was used as a positive control for MEK-dependent 
RAF inhibitor rescue; MITF was used as a positive control for MAPK-independent rescue.  
Consistent with the screening identification of AXL, we found that AXL was able to confer 
resistance to RAF, MEK, and RAF+MEK inhibition.  (Fig. 3.2)  Notably, AXL did not confer 
robust ERK inhibitor resistance, a finding that stands in contrast to the ERK inhibitor resistance 
observed in MAPK pathway inhibitor resistant cell lines.  Nonetheless, these validation assays 
confirm the screening phenotype that AXL is sufficient to confer resistance to RAF and MEK 
inhibition. 
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Figure 3.2: Overexpression of AXL confers resistance to RAF, MEK, and RAF+MEK, 
but not ERK, inhibition. 
Following expression of indicated ORFs, viability was measured after 4 days of treatment 
with 2 µM PLX4720 (RAFi), 200 nM AZD6244 (MEKi), 2 µM PLX4720 + 200 nM 
AZD6244, or 2 µM 11e (ERKi).  MEK is a negative control; RAF is a positive control for 
MAPK-dependent rescue; MITF is a positive control for MAPK-independent rescue. 
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3. Overexpression of AXL confers Akt activation and rescue of pERK following MAPK 
pathway inhibitor treatment.   
To elucidate the mechanism of AXL-mediated resistance to MAPKi, we overexpressed AXL in 
sensitive cell lines (Fig. 3.3; MEK is a negative control, RAF1 a positive control for MAPK 
pathway reactivation in the presence of RAF inhibition).  We observed that AXL has little effect 
on ERK phosphorylation at baseline; however, upon treatment with RAF, MEK, or RAF+MEK 
inhibitors, AXL expression preserved both ERK phosphorylation and Cyclin D1 expression.  The 
strength of pERK rescue was comparable to that effected by RAF1 following PLX4720 
treatment.  (Enhanced ERK phosphorylation following ERK inhibition is a putative feedback 
effect we have commonly observed.) We also noted that AXL expression induces Akt 
phosphorylation, which is further augmented by MAPK pathway inhibitor treatment.  Unlike 
pERK reactivation, Akt activation is not commonly observed following expression of resistance 
effectors (e.g., no increase in pAkt following RAF1 expression, right lanes), although there is 
some evidence that PI3 kinase pathway dysregulation may promote melanoma cell survival 
following RAF inhibition in vivo [117].  Thus, ectopic AXL expression conferred two distinct 
phenotypes: activation of Akt, and rescue of ERK phosphorylation following MAPK pathway 
inhibitor treatment. 
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Figure 3.3: Overexpression of AXL confers Akt activation and rescue of pERK following 
MAPK pathway inhibitor treatment. 
Following expression of indicated ORFs in A375 cells, lysates were harvested following 
overnight treatment with 2 µM PLX4720 (RAFi), 200 nM AZD6244 (MEKi), 2 µM PLX4720 
+ 200 nM AZD6244, or 2 µM 11e (ERKi).  MEK is a negative control; RAF is a positive 
control for MAPK pathway reactivation. 
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4. Stimulation with AXL ligand GAS6 confers Akt activation and, upon MAPK inhibitor 
treatment, rescue of ERK phosphorylation.   
To confirm that pAkt induction and pERK rescue are not artifacts of ectopic AXL 
overexpression, we also assessed whether endogenous AXL could mediate these responses.  We 
used A375, a MAPK pathway inhibitor sensitive cell line that, unusually, expresses AXL (but 
not it ligand, GAS6 ligand (thus, AXL is inactive in these cells at baseline).  Upon stimulation 
with recombinant GAS6 (1000 ng/mL), we observed induction of pAkt, which was further 
potentiated by the RAF inhibitor PLX4720.  We also observed an increase in pERK following 
GAS6 stimulus (DMSO wells).  Moreover, in the context of PLX4720 treatment, GAS6 effected 
a complete rescue of pERK levels.  (Fig. 3.4).  Whereas AXL overexpression produced sustained 
pAkt phosphorylation, GAS6 stimulus caused transient pAkt activation and pERK rescue; the 
levels returned to baseline within 2 hrs. after stimulus.  At later timepoints, AXL expression 
levels also decreased, an observation consistent with stimulus-dependent receptor internalization 
and degradation.  Although the kinetics differed between ectopic AXL expression and GAS6 
ligand exposure, these experiments confirm that endogenous AXL is able to mediate activation 
of both Akt and ERK.   
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Figure 3.4: Stimulation with AXL ligand GAS6 confers Akt activation and, upon MAPK 
pathway inhibitor treatment, rescue of ERK phosphorylation. 
A375 cells, endogenously expressing AXL, were stimulated with the AXL ligand GAS6 
(1000 ng/mL) for the indicated length of time before harvest.  (a) Western blot.  (b) 
quantification of Western blot. 
(a)  
(b)  
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5. Re-activation of pERK, but not activation of Akt, confers resistance to MAPK pathway 
inhibitors. 
Prior experiments demonstrated that AXL can activate both MAPK and Akt pathways.  MAPK 
pathway reactivation is a known mechanism of resistance to RAF/MEK inhibition.  We sought to 
query whether Akt activation could also contribute to the observed AXL-mediated resistance.  
To this end, we expressed MEK1WT (negative control), constitutively active MEK1 (MEK1DD) or 
KRASG12V (positive controls), or constitutively active myristoylated Akt.  By western blot, we 
confirmed that myrAkt displayed robust Akt phosphorylation (Fig. 3.5A).  We then assessed the 
effects of each construct on MAPK pathway inhibitor resistance (Fig. 3.5B).  We found that, 
unlike MEK1DD and KRASG12V, myrAkt conferred no resistance to any tested inhibitor.  While 
this finding does not rule out the possible contribution of Akt in enhancing resistance mediated 
by other pathways, it does argue that Akt activation is not individually sufficient in vitro to 
confer resistance to MAPK pathway inhibition.  This conclusion is also consistent with the 
enhanced Akt phosphorylation seen after MAPK pathway inhibitor treatment; if pAkt were 
sufficient to cause resistance, it would be unclear why cells that experienced high pAkt following 
drug treatment would still be sensitive to drug.  We therefore conclude that AXL mediates 
resistance to MAPK pathway inhibitors via re-activation of ERK phosphorylation. 
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Figure 3.5: Re-activation of pERK, but not activation of Akt, confers resistance to 
MAPK pathway inhibitors. 
(a) A375 cells expressing MEK1 (negative control), MEK1DD (control for MAPK re-
activation without Akt activation), myrisoylated Akt (control for Akt activation without 
MAPK re-activation), or KRASG12V (control for MAPK re-activation and Akt activation) were 
treated overnight with 2 µM PLX4720.   
(b) In parallel, effects of constructs in (a) on viability in the presence of indicated MAPK 
inhibitors was assessed after 4d drug treatment.  PLX = 2 µM PLX4720 (RAFi); AZD = 200 
nM AZD6244 (MEKi), 11e = 2 µM VTX11E (ERKi). 
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6. In intrinsically resistant cell lines, AXL knockdown does not alter pERK signaling at 
baseline or following RAF inhibitor treatment.   
Having established the sufficiency of AXL to effect resistance to RAF/MEK inhibition, we next 
asked whether AXL expression was necessary for maintenance of intrinsic resistance.  To do so, 
we leveraged both shRNA knockdown and small molecule AXL inhibition.  First, we noted that 
despite robust knockdown, AXL shRNAs did not alter ERK phosphorylation either at baseline, 
or following PLX4720 treatment (Fig. 3.6).  Although we cannot exclude the possibility that 
residual AXL expression following knockdown continues to mediate ERK signaling in these 
cells, the highly efficient knockdown suggests that this explanation is unlikely.  Rather, this 
finding suggests that, although overexpressed AXL is sufficient to reactivate the MAPK 
pathway, endogenous AXL may not directly influence MAPK pathway signaling levels at 
baseline or in the context of RAF inhibition. 
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Figure 3.6: In intrinsically resistant cell lines, AXL knockdown does not alter pERK 
signaling at baseline or following RAF inhibitor treatment. 
Indicated cell lines were infected with indicated shRNAs targeting AXL or control hairpin, 
selected, and treated overnight with or without 2 µM PLX4720 (RAFi).  Effects on MAPK 
signaling were assessed by Western blot. 
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7. In intrinsically resistant cell lines, AXL knockdown does not reproducibly sensitize to 
RAF inhibition. 
Next, we queried whether AXL knockdown could re-sensitize intrinsically resistant cells to 
MAPK pathway inhibition.  Following infection with either control or AXL shRNAs, cells were 
re-seeded for pharmacologic growth inhibition assays (Fig. 3.7).  One shRNA targeting AXL 
(shAXL.575) did confer a left shift in GI50 in some lines (RPMI7951 and Wm793), indicating 
sensitization.  However, this shRNA had a more modest in other intrinsically resistant lines 
(Hs294T and IGR39).  Moreover, this shRNA also shifted the GI50 value for the negative 
control sensitive cell line tested (A375).  Finally, this effect was not phenocopied in any line by a 
second shRNA displaying almost equivalent knockdown (shAXL.5353).  In aggregate, these 
findings suggest that AXL knockdown may have minimal effects on sensitivity to RAF 
inhibition and raise the possibility that left-shift observed with shAXL.575 in some cell lines was 
an off-target effect.   
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Figure 3.7: AXL knockdown does not reproducibly sensitize intrinsically resistant lines 
to RAF inhibition.  
Indicated cell lines were infected with indicated shRNAs targeting AXL or control hairpin, 
selected, reseeded, and viability measured following 4 days of PLX4720 20 treatment at the 
indicated doses. 
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8. Following ectopic AXL expression, AXL inhibitors abrogate AXL-mediated pAkt 
induction and pERK rescue. 
To determine if pharmacologic inhibition of AXL might sensitize intrinsically resistant 
melanoma cells to RAF/MEK inhibition, we used three small-molecule AXL inhibitors: R428, 
XL184, and XL880.  Here, we used drug concentrations that achieved maximum inhibition of 
phosphorylation of ectopic AXL while minimizing cellular toxicity (data not shown).  To 
confirm the efficacy of the selected doses, we overexpressed either MEK1 (negative control) or 
AXL in A375 and treated cells with each AXL inhibitor alone or in combination with PLX4720.  
As expected, we saw that ectopic AXL expression led to AXL autophosphorylation, increased 
basal Akt phosphorylation, and rescued pERK and Cyclin D1 levels following PLX4720 
treatment.  However, co-treatment with the AXL inhibitors at the optimized doses diminished or 
abrogated AXL autophosphorylation, induction of pAkt, and rescue of pERK and Cyclin D1 
levels following RAF inhibitor treatment (Fig. 3.8).  These effects were similar to those observed 
following concomitant knockdown of overexpressed AXL (right lanes).  Thus, the AXL 
inhibitors restored signaling, both at baseline and following RAF inhibition, to that observed in 
the MEK1-expressing negative controls (left lanes).  We therefore concluded that these AXL 
inhibitors, at the concentrations tested, are effective loss-of-function reagents for AXL. 
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Figure 3.8: Following ectopic AXL expression, AXL inhibitors abrogate AXL-mediated 
pAkt induction and pERK rescue. 
Following expression of indicated ORFs (MEK = negative control), A375 cells were treated 
with AXL inhibitors R428 (500 nM), XL184 (3 µM), or XL880 (100 nM), in the presence or 
absence of 2 µM PLX4720 (RAFi).  Effects of the AXL inhibitors on AXL-mediated pAkt 
induction and pERK rescue were assessed by Western blot. 
77 
 
9. In intrinsically resistant lines, AXL inhibitors do not alter pAkt or pERK levels at 
baseline or following RAF inhibitor treatment. 
Having validated the utility of small molecule AXL inhibitors for pharmacologic blockade of 
AXL function, we then queried their signaling effects on cell lines endogenously expressing 
AXL.  In three intrinsically resistant lines (Hs294T, RPMI7951, and IGR39), we found that 
treatment with the AXL inhibitors had no effect on basal ERK phosphorylation, residual pERK 
levels following PLX4720 treatment, or pAkt levels (Fig. 3.9).  Because basal AXL 
autophosphorylation was not detectable in these cells, we cannot exclude the possibility that 
these inhibitors are not effectually inhibiting putative signaling from endogenous AXL.  
Nonetheless, finding is consistent with the lack of effect of AXL shRNAs on these signaling 
mediators.  Cumulatively, this loss-of-function evidence suggests that, in intrinsically resistant 
lines, AXL signaling does not contribute substantially to basal pAkt levels, pERK levels, or 
residual pERK levels following RAF inhibitor treatment.   
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Figure 3.9: In intrinsically resistant lines, AXL inhibitors do not alter pAkt or pERK 
levels at baseline or following RAF inhibitor treatment. 
Intrinsically resistant lines were treated overnight with AXL inhibitors R428 (500 nM), 
XL184 (3 µM), and XL880 (100 nM), in the presence or absence of 2 µM PLX4720.  Lysates 
were harvested an assessed for pAkt and pERK by Western blot. 
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10. AXL inhibitors do not sensitize intrinsically resistant lines to RAF inhibition. 
As an additional test of whether AXL is required for maintenance of the intrinsic resistance 
phenotype, we measured PLX4720 GI50 values, across multiple intrinsically resistant lines in the 
presence or absence of each AXL inhibitor.  We consistently observed minimal if any shift in the 
PLX4720 GI50 following AXL inhibition (Fig. 3.10).  This data, which is consistent with the 
aggregate interpretation of the shRNA knockdown data (Fig. 3.7) as well as with the lack of 
measurable signaling effects of AXL inhibitors in these cell lines, suggests that AXL is not 
required for maintenance of intrinsic resistance to MAPK pathway inhibition in BRAFV600-
mutant melanoma. 
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Figure 3.10: AXL inhibitors do not sensitize intrinsically resistant lines to RAF 
inhibition. 
Melanoma cell lines intrinsically resistant to MAPK pathway inhibitors, treated with or 
without a fixed dose of the indicated AXL inhibitors, were assayed for sensitivity to PLX4720 
(RAFi). 
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Discussion and future directions 
Together, the work presented in this chapter has used the intersection of functional resistance 
screens and expression profiling data to nominate AXL as a candidate effector of intrinsic 
resistance to MAPK pathway inhibition in BRAFV600-mutant melanoma.  Subsequent functional 
validation work has revealed that, while AXL is sufficient to confer resistance to MAPK 
pathway inhibition, likely by re-activation of pERK, it is not required for maintenance of 
intrinsic resistance.   
A framework for querying targeted therapeutic resistance in cancer 
Together, these experiments have delineated several important observations.  First, they have 
nominated a framework for identifying candidate mediators of drug resistance.  For a given 
cancer lineage, genetic background, and targeted therapeutic intervention (e.g., MAPK pathway 
inhibition in BRAFV600-mutant melanoma), the paired availability of (1) steady-state gene 
expression profiling across a panel of sensitive and resistant lines and (2) functional genomic 
screening data is a potentially powerful combination.  While expression profiling can identify 
genes associated with intrinsic resistance or sensitivity, functional screening can identify which 
if any of those candidates are necessary or sufficient to effect the phenotype of interest.  In the 
particular case tested here, the intersection of ORF screens for acquisition of resistance with gene 
expression markers of innate resistance means that a candidate gene belonging to both lists is 
both expressed in resistant lines and sufficient to confer resistance; these two findings suggest 
that it is therefore a high-priority candidate mediator of intrinsic resistance.  It is important to 
point out, though, that many other possible variations exist: for example, an shRNA screen 
identifying genes whose loss confers resistance could similarly be intersected with expression 
profiles to query whether any of the hits are over-expressed at baseline in sensitive cells relative 
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to resistant cells.  To our knowledge, the systematic intersection of two such datasets, as 
performed here, constitutes a novel approach to understanding targeted therapeutic resistance in 
cancer. 
AXL biology 
In the particular case tested here, we identified AXL as associated with intrinsic resistance and 
sufficient to cause acquired resistance to MAPK pathway inhibition in BRAFV600-mutant 
melanoma.  AXL is a receptor tyrosine kinase belonging to the TAM family (TYRO3, AXL, 
MERTK).  AXL is widely expressed in normal tissues.  Like other RTKs, it undergoes 
heterodimerization and trans-phosphorylation upon binding its ligand, GAS6. [118] AXL has 
been shown to activate diverse downstream signaling pathways including Akt, MAPK, and NF-
κB [119, 120], although we observed activation only of Akt and MAPK.  While AXL was 
initially isolated from chronic myelogenous leukemia as a cDNA clone with transforming ability 
[121], few studies have specifically addressed it melanoma; those that have done so have noted 
(a) its expression in a subset of melanomas, with a possible link to enhanced invasive behavior 
[122], and (b) its expression in uveal melanoma, where stimulation with GAS6 was shown to be 
mitogenic [123].   
AXL in other resistance contexts 
Intriguingly, AXL has also been linked to acquired resistance to targeted therapeutics in other 
cancer contexts.  In EGFR-mutant non-small cell lung cancer (NSCLC), acquisition of erlotinib 
has been linked to gain of AXL expression as part of a broader program of epithelial-to-
mesenchymal cell state change. [124] AXL was shown to be individually sufficient to confer 
resistance to erlotinib when overexpressed.  After long-term exposure of an initially erlotinib-
sensitive NSCLC to erlotinib, outgrowing subclones that had acquired erlotinib resistance had 
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also acquired AXL.  Moreover, AXL was required for maintenance of this acquired erlotinib 
resistance.  Separately, in in vitro cultured-to-resistance experiments, AXL has also been shown 
to associated with the development of lapatinib resistance in ERBB2-expressing breast cancer 
[125] and to imatinib in KIT-mutant gastrointestinal stromal tumor [126].   
AXL is not required for maintenance of intrinsic resistance 
In specific context of MAPK pathway inhibitor resistance in BRAFV600-mutant melanoma, we 
identified AXL as both overexpressed in intrinsically resistant lines and sufficient to confer 
resistance.  Both of these index findings validated robustly in secondary assays, with AXL 
strongly expressed in resistant lines and both conferring resistance to and rescuing loss of pERK 
following inhibition of RAF, MEK, or RAF+MEK.  On the basis of this data, and building on 
our analysis framework, we queried a further hypothesis: that AXL was also required for the 
intrinsic resistance phenotype.  Through shRNA and small molecule inhibition studies, we 
demonstrated that AXL is in fact not required for the maintenance of intrinsic resistance.   
These results suggest several observations.  Most fundamentally, the finding that AXL is not 
necessary for intrinsic resistance is not inconsistent with the data that led us to formulate this 
hypothesis.  We selected genes that could confer resistance and that were expressed in resistant 
lines—not genes that were necessary for resistance.  To address that question directly, a 
potentially powerful approach would be an shRNA screen in an intrinsically resistant line, to 
identify genes whose loss enhanced sensitivity to RAF inhibition.  Indeed, such a screen could 
become another variation on the theme here established of intersecting functional screens with 
expression data, as it would be reasonable to query whether any hits were expressed more 
strongly at baseline in the resistant lines.  Thus, although AXL did not prove essential for 
maintenance of intrinsic resistance, this result it not inconsistent with the analytic framework that 
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nominated it; rather, it suggest future applications of this framework for continuing to query the 
phenomenon of intrinsic resistance.   
Moreover, the fact that AXL is not the sole and necessary effector of intrinsic resistance does not 
mean that it makes no contribution to intrinsic resistance.  Conceptually, this is consistent with 
our prior knowledge: RPMI-7951, for example, one of the intrinsically resistant, AXL-
expressing lines, is known to also harbor amplification of COT, another known resistance 
effector.  It would therefore be surprising if, in this context, abrogation of AXL alone were able 
to abrogate resistance, since COT would presumably still be active as an additional resistance 
mediator.  Thus, it remains eminently possible that AXL is one of multiple resistance effectors 
operant in the setting of intrinsic resistance, and that for that reason, inhibition of it alone does 
not restore sensitivity. 
Indeed, the data presented in this and the prior chapter suggest that intrinsic resistance is not a 
function of expression of a single resistance effector, but rather a broader question of cellular 
state.  The gene expression differences between sensitive and resistant classes are profound, and 
by no means confined to differential expression of AXL.  Gain or loss of many different 
mediators of resistance and sensitivity might therefore be at work in these lines; indeed, it is an 
open question whether the intrinsic resistant lines even have an underlying dependency on the 
MAPK pathway.  Moreover, we know that NF-κB activation is a master regulator of the 
transition between high-MITF/sensitive and low-MITF/resistant states.  We have shown that 
expression of AXL is induced by NF-κB activation, positioning AXL as a marker or downstream 
effector of the high-NF-κB intrinsic resistance state (perhaps one of many) rather than an 
upstream, essential master regulator.   
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Last, it is noteworthy that AXL confers resistance to inhibition of RAF, MEK, and RAF+MEK, 
but not to inhibition of ERK.  This phenomenon does not match the phenotype observed in 
intrinsically resistant lines, which are also resistant to ERK inhibition.  This discrepancy is 
highly consistent with the hypothesis that other resistance mediators, in addition to AXL, are at 
work in intrinsic resistance. 
In addition to our framework nominating AXL, another reason for interest in AXL was that it 
had been shown to be involved in resistance to targeted therapeutics in other contexts[124-126].  
Intriguingly, all of the therapeutics in question impinge on some way on the MAPK pathway: 
lapatinib in breast cancer, imatinib in GIST, and erlotinib in NSCLC.  Although none of these 
investigations queried the setting of intrinsic resistance, all showed that, following long-term 
exposure of sensitive parental cell lines to the drug in question, outgrowing subclones that had 
acquired inhibitor resistance had also acquired AXL expression.  In two cases, the authors 
showed that inhibition of AXL restored sensitivity to the drug in question.  [124, 125]  And in 
one case, the authors demonstrated both that AXL was sufficient to cause inhibitor resistance, 
and that acquisition of its expression was associated with a broader program of gene expression 
changes (in that case, epithelial-to-mesenchymal transition in NSCLC). [124] Although the 
NSCLC study concerned itself with acquired, rather than intrinsic, resistance, it is intriguing to 
note that, in their cellular context, an analysis analogous to ours would likely have identified 
AXL as well, as they found AXL to be both sufficient to confer resistance and differentially 
expressed between sensitive and resistant lines.  Yet they, unlike we, found that AXL was 
required for maintenance of the resistant phenotype.  A relevant question, therefore, since AXL 
has emerged in several resistance contexts, is whether these high-AXL, inhibitor resistant states 
share fundamental biological similarities, or whether AXL simply happens to be a pleiotropic 
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RTK capable of overcoming many inhibitors, or at least marking resistant states, in a relatively 
non-specific fashion.   
Conclusion 
Taken together, the results in this section offer a framework—intersection of functional genomic 
screens with steady-state expression profiling—for identifying high-priority candidate mediators 
of resistance.  In this case, we have nominated AXL as such a potential mediator but 
demonstrated that it is not required for sustaining intrinsic MAPK pathway inhibitor resistance in 
BRAFV600-mutant melanoma.  Overall, this result is consistent both with the phenotypic effects 
of AXL overexpression and with the profound expression differences between intrinsic 
sensitivity and resistance.  Nonetheless, the analytical method we present here may have broad 
future utility in nominating other genes whose expression patterns and functional properties 
make them compelling candidate effectors of drug resistance. 
Methods 
Cell culture 
All cells were maintained in medium supplemented with 10% FBS (unless otherwise indicated) 
and 1% penicillin/streptomycin.  The following cell lines were maintained in RPMI-1640: A375, 
Skmel28, UACC62, WM793, LOXIMVI,.  DMEM: A2058, Hs294T.  MEM: RPMI7951, 
Wm115.  DMEM with 15% FBS: IGR39.  All cell lines were obtained from in-lab stocks, from 
ATCC, or from Biological Samples Platform (Broad Institute). 
Gene expression and pharmacological analyses 
Gene expression (RMA normalized using ENTREZG v15 CDF), drug sensitivity (IC50 values), 
and genotyping data for BRAFV600-mutant melanoma cell lines were from the Cancer Cell Line 
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Encyclopedia (CCLE). [100] Pearson correlation coefficients (r) were computed between 
PLX4720 GI50 values and gene expression value.   
Candidate resistance ORFs were nominated on the basis of their ability to confer rescue to RAF, 
MEK, RAF+MEK, or ERK inhibition, in A375 cells, over a 4-day drug treatment.  
Subsequently, ORFs were validated in 9 additional melanoma cell lines; only the 107 ORFs with 
a validation Z score of >4.0 were considered for subsequent analyses. 
Constructs 
Lentiviral MEK1, RAF1, MITF-M, and AXL (clone 7F12), in vectors pLX980-Blast-V5 or 
pLX304-Blast-V5, were from The RNAi Consortium (Broad Institute).  Retroviral pBABE-Puro-
MEK1_WT, pBABE-Puro-MEK1_DD, pWZL-Blast-myrAkt1, and pWZL-Blast-KRAS_G12V 
constructs were from Cory Johannessen. 
shRNAs 
All shRNAs were in pLKO.1 vector. 
target  name  TRC identifier  target sequence 
Luciferase shLuc  TRCN0000072243 CTTCGAAATGTCCGTTCGGTT 
AXL  575  TRCN0000000575 CGAAATCCTCTATGTCAACAT 
AXL  5313  TRCN0000195353 CGTGGAGAACAGCGAGATTTA 
AXL  574  TRCN0000000574  CGAAAGAAGGAGACCCGTTAT 
Lentiviral infections  
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For validation of AXL rescue of MAPK pathway inhibitors, cells were seeded in 96-well plates 
and the following day were spin infected at 2250 rpm (1178 x g) for 1 hour at 30 °C using a 1:10 
dilution of ORF lentivirus.  Medium was changed immediately following infection.  After 3d, 
wells were drugged with MAPK pathway inhibitors at the indicated concentrations.  4 days later, 
cellular viability was read out by CellTiter-Glo. 
For myrAkt resistance experiments, A375 cells were seeded in 96w format (900 cpw) in 100 µL.  
The next day, polybrene was added to wells to 4 µg/mL final, 50 µL medium was removed, and 
50 µL retrovirus was added.  Remaining steps were performed as described above. 
For western blot studies, infections were performed in 12-well plates at the following densities: 
A375, 6e4; Wm793, 1.5e5; RPMI-7951, 1.25e5; IGR39, 6e4.  The next day, cells were changed 
to medium plus 4 µg/mL polybrene, virus was added (1:10 dilution for ORF lentiviruses, 1:50-
1:100 dilution for shRNA lentiviruses, 1:2 for retroviruses) and cells were spin infected at 2250 
rpm (1178 x g) for 30 minutes at 30 °C.  The following day, medium was changed to fresh 
medium plus puromycin (1 µg/mL final) or blasticidin (10 µg/mL final).  Following 3-5 days of 
selection, cells were changed again to fresh medium plus DMSO or indicated small molecule 
inhibitors.   
AXL inhibitors 
R428 was purchased from Symansis.  XL184 and XL880 were purchased from Selleck.  All 
compounds were resuspended in DMSO. 
AXL inhibitor treatment 
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For western blots and GI50 curves, cells were drugged first with PLX4720 (at serial dilutions for 
GI50 curves or at fixed 2 µM for western blots), then immediately drugged again with AXL 
inhibitors to the indicated final concentrations. 
Drug sensitivity assays 
For GI50 determinations following AXL knockdown, cells were re-seeded following selection to 
96-well plates at 1500-3000 cpw.  For GI50 determinations in the presence of AXL inhibitor, 
cells were seeded at the following densities: Cell lines: A2058, 3500; Hs294T, 6000; WM793, 
6000; RPMI7951, 4250; IGR39, 3000.  The day after plating, cells were drugged with AXL 
inhibitor (if indicated), then with serial dilutions of PLX4720 in medium DMSO to give final 
concentrations ranging from 100 µM to 31.62 nM, in half-log increments.  After 4 days of drug 
treatment, cellular viability was read using CellTiter-Glo and compared to DMSO wells.  GI50 
calculations were performed in GraphPad Prism.   
GAS6 stimulation 
Recombinant human GAS6, without carrier protein, was purchased from RND (885-GS-050), 
resuspended, aliquotted, and stored according to manufacturer’s instructions.  Prior to GAS6 
stimulation, cells were plated in full serum at 2e5 cpw in 12w plates.  The next day, cells were 
washed 1x in PBS, changed to fresh full-serum medium with DMSO or 2 µM PLX4720, and 
stimulated with GAS6 (1000 ng/mL final) over the indicated timecourse.   
Lysate harvesting 
Cells were harvested by washing 1x in PBS, applying sufficient lysis buffer to cover the well (~ 
40 uL for 12w plate, ~100 uL for 6w plate, ~250 µL for 10 cm plate), and removing lysis buffer.  
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Plates were not scraped and lysates were not pelleted.  Cells were lysed in 1% NP40 buffer 
(150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF and 1% NP-40), containing 
2x EDTA-free protease inhibitor cocktail (Roche) and 1x phosphatase inhibitors I and II (EMD).  
Lysates were quantitated by BCA, normalized, and denatured by boiling in sample buffer plus 20 
mM DTT. 
Western Blotting 
Transfers were on iBlot nitrocellulose membrane using setting P0.  Membranes were blocked 1 
hour at room temperature in LiCor blocking buffer.  Primary antibodies (1:1000 dilution unless 
otherwise indicated) were incubated overnight at 4°C in LiCor blocking buffer plus 0.1% Tween-
20.  Secondary antibodies (1:10,000 dilution, LiCor) were incubated at room temperature for 90 
minutes in LiCor blocking buffer plus 0.1% Tween-20 and 0.1% SDS.  Imaging was on a LiCor 
Odyssey infrared imager. 
The following primary antibodies were used at 1:1000 unless otherwise indicated.  CST = Cell 
Signaling Technology.  AXL (C44G1, CST 4566; 6C8, Sigma WH0000558M1); Cofilin (D3F9, 
CST 5175, 1:20,000); pERK (T202/Y204, D13.14.4E, CST 4370); tERK (L34F12, CST 4696); 
pAkt (S473, D9E, CST 4060); Akt (40D4, CST 2920); Cyclin D1 (NeoMarkers Ab-3 Rb-010-P, 
1:400); pTyr (4G10, Millipore); pAXL (Y702, D12B2, CST 5724).   
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CHAPTER 4.  MODULATING ACQUIRED MAPK PATHWAY INHIBITOR RESISTANCE:  
PERTURBING COT BY MODULATING NF-ΚB. 
Abstract 
Although the BRAF inhibitor vemurafenib has shown dramatic efficacy in BRAFV600-mutant 
melanoma, relapse (acquired resistance) is universal.  Prior work has elucidated overexpression 
of the kinase COT/MAP3K8 as a mechanism of acquired resistance to vemurafenib/PLX4720.  
COT is also expressed at baseline in some BRAFV600-mutant cell lines intrinsically resistant to 
PLX4720.  However, the prospects for COT as a therapeutic target are tempered by the lack of 
effective small molecule COT inhibitors.  For this reason, we sought to determine whether 
alternative avenues might exist to perturb COT expression and/or stability.  Of note, COT protein 
is highly labile and requires binding to NFKB1 p105 for stability.  We reasoned that targeting 
p105 might destabilize COT and impair COT-mediated resistance.  Indeed, shRNA knockdown 
of p105 was highly effective in decreasing both ectopic and endogenously expressed COT.  In 
ectopic contexts, p105 knockdown also decreased COT-mediated rescue of pERK following 
PLX4720 treatment and partially reversed COT-mediated PLX4720 resistance.  In cell lines 
endogenously expressing COT, however, knockdown of p105 or COT affected neither residual 
pERK following PLX4720 treatment nor resistance to PLX4720.  This finding suggests that 
COT, although sufficient to confer acquired resistance to MAPK pathway inhibitors, is not 
required for the maintenance of intrinsic resistance.  Cumulatively, this work provides a proof of 
principle that targeting binding partners can perturb resistance effectors but suggests that indirect 
targeting of COT may not be sufficient to overcome intrinsic resistance.   
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Introduction 
Background 
The impressive therapeutic responses associated with vemurafenib treatment in BRAFV600-
mutant melanoma have been tempered by the observation that all patients eventually relapse.  
[87] This phenomenon, in which an initially sensitive melanoma transitions to a resistant 
phenotype, is referred to as “acquired resistance.” Prior work in the Garraway lab and elsewhere 
has sought to elucidate mechanisms of acquired resistance, chiefly by searching for perturbations 
able to confer MAPK pathway inhibitor resistance on an otherwise sensitive cell line.   
One example of this approach was a genetic screen published from our lab. [92]  In this screen, a 
collection of ~600 kinases was screened for the ability to rescue viability in the A375 melanoma 
cell line following treatment with PLX4720 (the preclinical of vemurafenib).  Of the 9 kinases 
validated to confer statistically significant rescue, COT/MAP3K8 was nominated for further 
investigation as having the strongest resistance phenotype across multiple cell lines.   
COT: an effector of PLX4720 resistance 
COT/MAP3K8/TPL2 was originally identified as a transforming cDNA clone [127] that was 
subsequently shown to activate the MAPK pathway through its function as a MAP3K [128].  
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Since its initial discovery, COT has been shown to be of critical importance in the context of 
immune signaling.  COT is required for signaling cross-talk from inflammatory pathways to the 
MAPK pathway; it is also required for normal transcriptional response to innate immune stimuli 
such as LPS or other Toll-like receptor ligands. [129-131] 
Consistent with its annotation as a MAP3K, COT was found to confer resistance to PLX4720 
through reactivation of ERK phosphorylation.  In addition, two BRAFV600E cell lines, one 
melanoma and one colon, harbored copy number gains spanning the MAP3K8 locus; both lines 
were profoundly resistant to PLX4720.  Intriguingly, in melanocytes and in cell lines, COT 
displayed a reciprocal expression pattern with BRAF.  BRAFWT melanocytes express 
endogenous COT, but ectopic expression of BRAFV600E causes loss of COT.  Conversely, in 
A375 (a BRAFV600E melanoma cell line), ectopic COT was only moderately expressed from a 
CMV promoter; following knockdown of endogenous BRAF or treatment with PLX4720, 
however, ectopic COT expression was strongly potentiated.  [92] 
Cumulatively, these findings nominate COT as a putative target for overcoming acquired 
resistance.  Conceivably, COT inhibition could be administered concomitantly with vemurafenib 
or other MAPK inhibitors to forestall COT-mediated resistance or as salvage therapy following 
COT-driven relapse.  Unfortunately, COT inhibitors have yet to be deployed in the clinical arena  
[132-136], reviewed in [137]. 
NFKB1 p105 binds and stabilizes COT 
In light of our interest in NF-κB signaling in melanoma (detailed in other chapters), we 
considered the established links between COT function and NF-κB activity in inflammatory and 
immune-related signal transduction.  In particular, its link to the NF-κB pathway suggested a 
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potential means to perturb COT function.  NFKB1, one of the NF-κB family of transcription 
factors, is transcribed as a 105 kD inactive precursor (p105), containing both an N-terminal, 
transcriptionally active Rel homology domain, and a C-terminal inhibitory ankyrin repeat 
domain.  At baseline, the presence of the ankyrin repeat domain sequesters full-length p105 in 
the cytoplasm, where it is transcriptionally inactive.  Following stimulus, p105 is cleaved 
between the N-terminal and C-terminal domains, liberating the C-terminal ankyrin repeats for 
degradation and the N-terminal Rel homology domain (referred to as p50) for transcriptional 
activity.   
Notably, full-length, inactive NFKB1 p105 both stabilizes and sequesters COT through COT’s 
interaction with the C-terminal ankyrin repeats of p105; thus, p105 and COT reciprocally bind 
and stabilize each other. [138-141] The consequences of this binding are twofold: p105 is 
absolutely required for COT protein stability and expression, but binding to p105 blocks COT 
from accessing its downstream substrates [140-142].  Thus, p105-bound COT forms a latent 
reservoir of sequestered, inactive COT that can be liberated following stimulus-directed p105 
cleavage.  Once p105 cleavage—a feature of NF-κB pathway activation—liberates COT, COT is 
able to exercise its MAP3K functions before being rapidly degraded.   
The key role of p105 in COT stability and activity led us to hypothesize that targeting p105 
could provide an alternative means of COT perturbation, with possible therapeutic implications.  
To this end, we formulated two hypotheses.  First, we hypothesized that differences in p105 
levels or binding to COT might explain the reciprocal relationship of COT and BRAF observed 
in primary melanocytes and in A375 cells.  Second, we hypothesized that by perturbing p105, we 
could in turn perturb COT and COT-mediated rescue of pERK and resistance following 
PLX4720 treatment. 
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Results 
1. In melanocytes, introduction of BRAFV600E leads to loss of COT expression without 
accompanying decrease in p105 levels. 
To test the hypothesis that endogenous p105 is involved in reciprocal regulation of BRAF and 
COT levels, we considered two contexts in which this phenomenon has been demonstrated: 
melanocytes and melanoma cell lines.  BRAFWT melanocytes express COT at baseline, 
expression that was abrogated by the introduction of BRAFV600E (Fig. 4.1).  In light of the role of 
p105 in stabilizing COT, we predicted that loss of COT expression might be due, at least in part, 
to lower levels of p105 following introduction of BRAFV600E.  Surprisingly, however, we found 
that p105 levels increased following BRAFV600E introduction (Fig. 4.1).  The mechanistic basis 
of this observation is unknown, but it is inconsistent with the idea that the balance between COT 
and BRAF in melanocytes is controlled primarily by p105 levels.  Moreover, it has previously 
been shown that COT mRNA levels decrease following introduction of BRAFV600E.  [92] 
Together, these data suggest that reciprocal regulation of COT and BRAF does not depend on 
p105 but rather may operate through either transcriptional or other post-translational regulatory 
mechanisms. 
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Figure 4.1: In melanocytes, introduction of BRAFV600E leads to loss of COT expression 
without accompanying decrease in p105 levels. 
Expression of COT and p105 in melanocytes at baseline (L), or following introduction of 
BRAFV600E with or without co-treatment with the BRAF inhibitor PLX4720. 
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2. In melanoma cells, BRAF knockdown leads to enhanced expression of ectopic COT 
without accompanying increase in p105 levels. 
We next turned our attention to melanoma cell lines to query the possible role of endogenous 
p105 in modulating expression of ectopic COT.  We used the A375 melanoma cell line, which 
endogenously express BRAFV600E but not COT.  COT is detectable following lentiviral 
expression and is further upregulated upon concomitant knockdown of BRAF.  (Fig. 4.2) 
Because expression of COT in this context is driven by a constitutive CMV promoter, regulation 
of COT in this context is likely to be at the level of protein stability rather than transcription.  
Since p105 is a key regulator of COT protein stability, we predicted that enhanced COT 
expression following BRAF knockdown would be accompanied by either (a) increased p105 
levels or (b) constant total p105 levels but increased association between COT and p105.  To test 
the first possibility, we blotted whole-cell lysates (left panel) for p105 following introduction of 
COT, with or without knockdown of BRAF.  Knockdown of BRAF had no effect on p105 levels.  
We reasoned that even if total p105 levels remained constant, enhanced COT expression might 
be due to an increase in COT-p105 association.  To query this possibility, we 
immunoprecipitated COT (right panel) from the same lysates and then probed for p105.  Here, 
too, we observed no differences in COT-bound p105.  Thus, although the mechanism underlying 
reciprocity of BRAFV600E expression and COT expression and/or protein stability remains 
unknown, the preceding experiments argue that p105 is not the key mediator of this regulation 
either in melanocytes or in melanoma cells. 
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Figure 4.2: In melanoma cells, BRAF knockdown leads to enhanced expression of 
ectopic COT without accompanying increase in p105 levels. 
In A375 melanoma cells expressing negative control (LacZ) or V5-tagged COT, levels of total 
p105 were measured in whole-cell lysates (WCL) following knockdown of BRAF.  
Additionally, levels of COT-bound p105 were measured by immunopreciptiation with V5 (IP 
V5). 
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3. p105 super-repressor enhances ectopic COT expression but does not impair COT-
mediated rescue of pERK.   
Having determined that differential expression of endogenous p105, or altered interaction 
between COT and endogenous p105, might not be a primary determinant of the balance between 
COT and BRAF expression in melanocytes or melanoma cells, we turned to our second 
hypothesis: that perturbation of p105 could modulate COT function.  In particular, we 
hypothesized that sequestration of COT by p105 might prevent its ability to re-activate MAPK 
and/or drive PLX4720 resistance. [141] To this end, we used a p105 super-repressor construct 
(p105 SR).  This construct is N-terminally deleted, encoding only the inhibitory C-terminal 
ankyrin repeat domains, and it carries a S930A mutation, which prevents its phosphorylation and 
degradation. [143] Because this super-repressor can neither be phosphorylated nor targeted for 
degradation, it should permanently sequester COT.  As negative controls, we used an empty 
vector and an IκBα super-repressor; IκBα is structurally and functionally homologous to the 
inhibitory C terminal ankyrin repeats of p105, but has not been shown to interact with COT.  We 
found that expression of the p105 super-repressor led to strongly increased levels of COT (Fig. 
4.3, lanes 4 vs. 6 and 10 vs. 12).  Conversely, expression of COT also led to increased expression 
of p105, whether endogenous (lanes 1 vs. 4 or 7 vs. 10) or from the super-repressor construct 
(lanes 3 vs. 6 and 9 vs. 12).  These results imply a mutual stabilization between p105 and COT.  
Moreover, expression of the super-repressor had no effect on pERK of pMEK levels following 
PLX4720 treatment (1 μM, 18 hrs.; lanes 10 vs. 12).  These results suggest that, while p105 SR 
may sequester COT, sufficient free COT remains to activate pERK in the presence of PLX4720.  
We therefore concluded that sequestration of COT by p105 is insufficient to abrogate COT-
mediated resistance.   
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Figure 4.3: p105 super-repressor enhances ectopic COT expression but does not impair 
COT-mediated rescue of pERK.   
In A375 cells (L) expressing negative control (MEK) or COT, effects of expression of a non-
cleavable, constitutively COT-bound p105 super-repressor (p105 SR) on ectopic COT levels 
and COT-mediated rescue of pERK following PLX4720 treatment.  pBp (empty vector) and 
IκBα SR are negative controls.  RPMI-7951 (R) expresses endogenous COT. 
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4. NFKB1 knockdown decreases p105 levels more effectively than does IL-1β-mediated 
p105 cleavage. 
Since increased levels of p105 led to increased levels of COT, we reasoned that decreasing levels 
of p105 might inhibit COT function by decreasing COT levels.  We compared two strategies for 
decreasing p105 levels: stimulus-driven p105 cleavage using IL-1β, and shRNA knockdown of 
NFKB1.  We compared several doses and timepoints against five p105 shRNAs.  (Fig. 4.4) We 
found that IL-1β achieved a maximum of ~50% reduction in p105 levels, and that this effect was 
largely durable up to 5 days.  In contrast, NFKB1 shRNAs achieved a ~90% reduction in p105 
levels.  Since shRNAs were significantly more effective than IL-1β at depleting p105, three p105 
shRNAs (6517, 6518, 6520) displaying excellent knockdown and minimal toxicity were selected 
for future studies.  Notably, one selected shRNA, 6517, targets the 3’ UTR of the NFKB1 
transcript and therefore can be used in combination with the p105 SR construct. 
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Figure 4.4: NFKB1 knockdown decreases p105 levels more effectively than does IL-1β-
mediated p105 cleavage. 
In A375 cells, p105 levels were measured following NFKB1 knockdown (L) or IL-1β-
mediated cleavage (R) at various IL-1β doses/timepoints.   Top: western blot.  Bottom: 
quantification of western blot. 
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5. Knockdown of p105 NFKB1 decreases ectopic and endogenous COT expression. 
To query the reciprocal effects of modulation of p105 or COT on each other, we examined two 
contexts: A375 cells expressing exogenous COT (Fig. 4.5A), and endogenously COT-amplified 
BRAFV600E cell lines (RPMI-7951 and OUMS23).  (Fig. 4.5B and Fig. 4.5C) (Western blots for 
these experiments, by cell line, are presented in Fig. 4.5A-C; quantification of these experiments, 
by target, is presented in Fig. 4.6-4.8.) First, we examined how perturbation of COT altered p105 
levels.  Consistent with prior findings, introduction of COT into A375 led to increased p105 
levels (Fig. 4.5A), presumably through reciprocal p105/COT stabilization.  Conversely, in all 
cell lines, shCOT led to modest decreases in p105 expression (Fig. 4.5A-C).  shCOT also 
provided a positive control for loss of COT following subsequent perturbations.   
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Figure 4.5: Knockdown of p105 NFKB1 decreases ectopic and endogenous COT 
expression. 
In (a) A375 cells ectopically expressing MEK (negative control) or COT, (b) RPMI-7951 
cells endogenously expressing COT, or (c) OUMS23 cells endogenously expressing COT, 
effect of shNFKB1 or p105 super-repressor on levels of p105, COT, and pERK with or 
without PLX4720 treatment  (1 µM overnight). shCOT is a positive control for loss of COT; 
shLuc and pBp are negative controls. 
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(continued) 
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6. Knockdown of NFKB1 decreases p105 levels.   
To understand how perturbing p105 affected COT, we used shRNAs targeting NFKB1.  These 
shRNAs were highly effective in all cellular contexts (typically >80% knockdown, Fig. 4.6).  We 
also, however, considered the effect of the p105 SR.  As observed previously (Fig. 4.3), p105 SR 
increased COT protein levels in both exogenous (Fig. 4.5A) and endogenous (Fig. 4.5B and Fig. 
4.5C) contexts, suggesting that COT was binding to and being stabilized by the p105 SR.  The 
p105 SR did not, however, impair COT-mediated pERK rescue following PLX4720 treatment.  
We reasoned that this might be due to competition between the p105 SR, which permanently 
sequesters COT, and endogenous p105, from which COT could still be liberated to effect pERK 
rescue.  Conversely, it is possible that, in the setting of shNFKB1, residual p105 might still 
suffice to stabilize COT and allow its activity.  In this context, addition of p105 SR should 
compete COT away from the small amount of remaining endogenous p105, permanently 
sequestering and inactivating it.  To address these two questions, we simultaneously expressed 
the p105 SR while using a 3’ UTR-targeted shRNA to abrogate endogenous p105.  This 
condition was not tested in A375+COT; in OUMS23, inadequate p105 SR expression was 
achieved.  In RPMI-7951, however, p105SR was adequately expressed such that approximately 
75% of expressed p105 was in fact p105SR. 
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Figure 4.6: Knockdown of NFKB1 decreases p105 levels.  
p105 levels in A375 (exogenously expressing COT), RPMI7951, and OUMS23 
(endogenously expressing COT), following NFKB1 knockdown (R) or other indicated 
perturbations, with or without 1 µM overnight PLX4720 treatment (-/+).  Percentage is 
relative to negative control shLuc + DMSO (black line).  Where expressed, p105 super-
repressor is quantified separately.  Quantification is from Figure 4.5A-C. 
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7. Knockdown of p105 NFKB1 decreases COT expression in exogenous and endogenous 
contexts.   
Following these perturbations—shCOT, shNFKB1, p105 SR, and the combination of shNFKB1 
and p105 SR—COT levels were quantified (Fig. 4.7).  As expected, COT levels increased 
robustly upon expression p105 SR alone; conversely, shCOT suppressed COT levels.  We then 
assessed the effect of p105 knockdown on COT levels.  Strikingly, we found robust suppression 
of COT expression following shNFKB1 (~50% in A375, ~80% in RPMI-7951 and OUMS23).  
In many cases, the effect of shNFKB1 on COT levels was actually greater than the effect of 
shCOT itself.  This finding seemingly endorsed our core hypothesis that COT and p105 levels 
reciprocally regulate each other, and that perturbing one is a potentially useful means to altering 
levels of the other.  With respect to the p105 SR construct, in RPMI-7951, the majority of p105 
was successfully replaced by p105 SR (Fig. 4.6), leading to a full restoration of COT levels and 
demonstrating that the effects of shNFKB1 on COT levels are not due to off-target effects. 
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Figure 4.7: Knockdown of p105 NFKB1 decreases COT expression in exogenous and 
endogenous contexts.   
COT levels in A375 (exogenously expressing COT), RPMI7951, and OUMS23 
(endogenously expressing COT), following NFKB1 knockdown (R) or other indicated 
perturbations, with or without 1 µM overnight PLX4720 treatment (-/+). Percentage is relative 
to negative control shLuc + DMSO (black line). Quantification is from Figure 4.5A-C. 
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8. Knockdown of p105 NFKB1 decreases residual pERK following PLX4720 treatment in 
the setting of exogenous, but not endogenous, COT expression. 
Next, we assessed the effect of these perturbations of COT levels on its ability to reactivate the 
MAPK pathway, as measured by pERK, in the presence of the BRAF inhibitor PLX4720 (Fig. 
4.8).  Results are presented normalized to the amount of pERK rescue achieved at baseline.  
(E.g., if A375+COT+shLuc has 40% of basal pERK remaining after PLX4720 treatment, and 
A375+COT+shCOT has 20% of basal of pERK remaining after PLX4720 treatment, the 
normalized value for A375+COT+shCOT is 50% of rescue remaining.) As expected, parental 
A375 cells show total loss of pERK upon PLX4720 treatment; shCOT abrogated the majority of 
COT-mediated pERK rescue (~20% rescue remaining for 2/3 shRNAs), providing a technical 
positive control.  We next considered the effects of shNFKB1.  Although its effects were more 
modest than shCOT, shNFKB1 was able measurably to suppress COT-mediated rescue of pERK 
in the setting of A375+COT (~75% rescue remaining for 2/3 shRNAs).  This finding provides a 
key confirmation of our hypothesis that perturbations of p105 could perturb COT-mediated 
MAPK pathway reactivation. 
We then turned our attention to residual pERK in the setting of endogenous COT expression.  Of 
note, RPMI7951 is the only intrinsically resistant melanoma line with amplified COT; moreover, 
it is the only intrinsically resistant melanoma line that maintains pERK following MAPK 
pathway inhibitor treatment (cf. Fig. 2.3C).  We therefore hypothesized that suppression of COT 
might suppress this residual pERK.  In RPMI-7951 and OUMS23, shCOT, the positive control in 
this experiment, achieved measurable COT suppression (~50% remaining) yet did not alter 
pERK rescue.  Moreover, shNFKB1—despite suppressing COT more profoundly than shCOT 
itself (~25% remaining, Fig. 4.7)—did not alter residual pERK following PLX4720 treatment 
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(Fig. 4.8) Even in the context of the p105 SR, where any wild-type p105 enduring after knock-
down would have to compete with an excess of p105 SR, we saw no effect on pERK rescue (Fig. 
4.8).  These findings suggest that, in cell lines that endogenously express COT and are 
intrinsically resistant to PLX4720, perturbation of COT directly or by shNFKB1 is unable to 
modulate residual pERK following PLX4720 treatment. 
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Figure 4.8: Knockdown of p105 NFKB1 decreases residual pERK following PLX4720 
treatment in the setting of exogenous, but not endogenous, COT expression. 
Residual pERK levels following PLX4720 treatment in A375 (exogenously expressing COT), 
RPMI7951, and OUMS23 (endogenously expressing COT), following NFKB1 knockdown 
(R) or other indicated perturbations.  Percentage is relative to pERK maintained in negative 
control (shLuc) following PLX4720 treatment (black line).  Quantification is from Figure 
4.5A-C. 
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9. Knockdown of NFKB1 partially resensitizes A375+COT cells to PLX4720. 
As a further test of the ability of COT and NFKB1 perturbations to affect COT-mediated 
resistance, we performed pharmacological growth inhibition experiments on cells perturbed as 
above.  A375+COT and RPMI-7951 were used for these experiments; OUMS23 was omitted 
due to technical difficulties.  In A375+COT, as a positive control, COT shRNAs robustly re-
sensitized cells to PLX4720 (Fig. 4.9A).  Consistent with the weaker effect of shNFKB1 in 
decrementing COT and pERK rescue, shNFKB1 only marginally resensitized cells to PLX4720.  
Indeed, measured PLX4720 GI50 was proportional to the amount of COT remaining across 
various perturbations (Fig. 4.9B).  Thus, it appears that the ~25% reduction in residual pERK 
effected by shNFKB1 (Fig. 4.8 was sufficient to effect only a marginal change in resistance to 
PLX4720. 
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Figure 4.9: Knockdown of COT partially resensitizes A375+COT cells to PLX4720.  
Top: shCOT substantially resensitizes A375+COT to PLX4720, whereas shNFKB1 effects 
only a modest resensitization (2/3 hairpins) 
Bottom: Correlation between % COT remaining and PLX4720 GI50 for various perturbations 
of A375+COT. 
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10. Knockdown of neither COT nor NFKB1 sensitizes RPMI-7951 to PLX4720.   
We queried whether a similar result obtained in RPMI-7951.  Here, we found that neither shCOT 
nor shNFKB1 reproducibly shifted the GI50 for PLX4720 (Fig. 4.10).  This finding is consistent 
with our prior observations that neither perturbation altered residual ERK following PLX4720 
treatment.  Thus, in the setting of endogenous COT expression in RPMI-7951, modulation of 
COT either by shCOT or by shNFKB1 appears insufficient to alter the phenotype of intrinsic 
resistance to PLX4720 and maintenance of MAPK pathway activity following PLX4720 
treatment. 
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Figure 4.10: Knockdown of neither COT nor NFKB1 sensitizes RPMI-7951 to PLX4720.  
Effects of control constructs, the p105 SR alone or in combination with knockdown of 
endogenous p105, shCOT, and shNFKB1 on PLX4720 GI50. 
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Discussion and future directions 
COT and p105 interaction in melanoma 
These investigations have revealed several aspects of COT biology and interaction with p105 
NFKB1.  First, a reciprocal stabilization between COT and p105, similar to that reported in 
immune contexts [138-140], is evident in melanoma as well.  Our work therefore demonstrates 
that this aspect of COT biology is conserved across cellular contexts.  As a consequence, we 
found that perturbing p105 also modulates COT levels in melanoma.  Indeed, in many cases, 
knockdown NFKB1 was more effective at reducing COT levels than was knockdown of COT 
itself.  Thus, our core hypothesis of using p105 to perturb COT expression was validated. 
Perturbing ectopic COT 
The motivation for perturbing COT by perturbing p105 was to determine if p105 suppression 
might attenuate COT-mediated reactivation of pERK and therefore COT-dependent resistance 
following treatment with a RAF inhibitor.  In the context of A375 cells exogenously expressing 
COT, it is known that COT is the primary mediator of PLX4720 resistance.  Consistent with this 
fact, knockdown of COT in A375 exogenously expressing COT almost totally abrogated pERK 
rescue following PLX4720 treatment.  Similarly, p105 knockdown also attenuated COT 
expression and pERK rescue (albeit in both cases less than the attenuation observed with 
shCOT).  Thus, in an exogenous context, where COT is known to be a predominant resistance 
effector, knockdown of p105 is capable of affecting COT-mediated MAPK pathway reactivation.  
However, in this specific setting of A375, the fundamental limitation appears to be one of effect 
size: because shNFKB1 was less effective than shCOT at suppressing COT levels, shNFKB1 in 
turn led to only a ~25% reduction in pERK. 
Perturbing endogenous COT 
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We obtained different results in the setting of endogenous COT expression (RPMI-7951 and 
OUMS23).  Of note, RPMI-7951 is distinguished from other intrinsically resistant melanoma 
lines not only in its expression of COT, but also in retaining pERK following MAPK pathway 
inhibitor treatment (cf. Fig. 2.3C)—a phenomenon COT is sufficient to effect.  In RPMI-7951 
(and OUMS23), shNFKB1 was typically at least as effective as shCOT in reducing COT 
expression, thus eliminating a technical barrier in A375 to adequate abrogation of pERK rescue.  
However, shCOT and shNFKB1 neither altered residual pERK following PLX4720 treatment, 
nor, in RPMI-7951, re-sensitized cells to PLX4720.  There are at least two, non-mutually 
exclusive possibilities to explain these results.   
First, shCOT and/or shNFKB1 may have inadequately suppressed COT levels in RPMI-7951 
and OUMS23.  This appears to be the case in A375+COT, where the stronger COT suppression 
achieved by shCOT was sufficient to abrogate pERK rescue and phenotypic resistance, whereas 
the weaker COT suppression achieved by shNFKB1 was not.  In RPMI-7951 and OUMS23, 
shCOT was less effective at suppressing COT than in A375+COT, suggesting that, in these cell 
lines, residual COT could have continued to phosphorylate ERK and maintain viability in the 
presence of PLX4720.  This explanation appears less likely in the contest of shNFKB1, however, 
as knockdown of p105 frequently led to efficient suppression of endogenous COT.  In either 
case, testing this hypothesis would require a more effective way to suppress COT expression or 
function.  Unfortunately, we lack tools to do so: shCOT provided inadequate knockdown, and 
small molecule COT inhibitors have suboptimal potency and specificity.   
Second, COT is not required for maintenance of pERK rescue and/or intrinsic resistance 
following PLX4720 to RPMI-7951 and OUMS23.  Consistent with this hypothesis, shCOT did 
abrogate pERK rescue and phenotypic resistance in A375+COT, where COT is known to be the 
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only kinase rescuing pERK following PLX4720 treatment.  Although shCOT achieved less COT 
knockdown in RPMI-7951 and OUMS23 than in A375+COT, shNFKB1 in RPMI-7951 and 
OUMS23 suppressed COT in those lines to a degree comparable to that of shCOT in 
A375+COT, yet showed no effect on pERK or drug resistance, suggesting that other mediators 
of pERK rescue and resistance might be active.   
The possibility that COT is not required for maintenance of intrinsic resistance in cell lines such 
as RPMI-7951 and OUMS23 is noteworthy.  Indeed, it is consistent with data from several other 
sources.  First, RPMI-7951 is among the high-NF-κB, high-AXL melanoma cell lines studied in 
Chapters 2 and 3.  Much as AXL, though individually sufficient to confer MAPK pathway 
inhibitor resistance, was found not to be required for maintenance of intrinsic resistance, these 
data suggest that the same is true of COT.  Indeed, given that RPMI-7951 express not only COT 
but also AXL, another known resistance effector, it would have been surprising if perturbing 
only COT was sufficient to render the cells sensitive to MAPK pathway inhibition.  Moreover, 
the simultaneous expression of multiple resistance effectors is consistent with findings from 
patient samples, where, for example, COT amplification has been found to co-exist with an 
activating MEK1C121S mutation that also confers RAF inhibitor resistance. [144]   
The possibility of multiple resistance effectors operating at once suggests several observations.  
First, targeting resistance (whether intrinsic or acquired) may require more than simply targeting 
a single resistance effector shown to be expressed in the resistant context.  On the contrary, 
targeting multiple resistance effectors may be required.  Second, what controls the balance 
between these resistance effectors? Do they antagonize each other or synergize with each other? 
Are they mutually controlled by a master regulator? Are they present in the same cells or are 
they contained within subpopulations of the relapsing tumor?  
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The characterization of an intrinsically resistant cellular state in Chapter 2 suggests potential 
answers to these questions.  In initially sensitive cell lines continuously cultured in PLX4720, in 
at least some cases, resistant subclones gained COT expression, but in the context of a broader 
transition to the high-NF-κB state.  Although this finding is an example of acquired, rather than 
intrinsic, resistance, it may suggest that COT as a resistance effector does not operate in 
isolation, but rather is one effector engaged by a broader cell state transition such as that 
characterized in Chapter 2.  Indeed, as discussed in Chapter 2, it is not certain that cells in the 
intrinsically resistant state retain any fundamental dependency on the MAPK pathway.  If not, 
then it appears unlikely that targeting any individual resistance effector would confer sensitivity. 
Ultimately, a definitive demonstration of the role of COT in RPMI-7951 and OUMS23 would 
require more effective suppression of COT: continued rescue of pERK and continued PLX4720 
resistance in the setting of definitively ablated COT signaling would demonstrate that COT was 
not the only operant resistance mechanism.  In the absence of better loss-of-function reagents to 
carry out this experiment, however, the cumulative picture of intrinsic MAPK pathway inhibitor 
resistance appears to be one of a broad cell-state dichotomy differentiating sensitivity from 
resistance, rather than a background of baseline sensitivity on which expression of individual 
resistance effectors is superimposed. 
Conclusion 
In summary, we have elucidated several features of p105/COT biology in melanoma.  We have 
shown that they interact in melanoma and that their levels are reciprocally regulated.  Reciprocal 
regulation of BRAF/COT levels appears not to depend upon altered p105 levels or COT-p105 
binding.  shNFKB1, to a greater extent than IL-1β, suppresses p105 and hence COT levels.  
Indeed, following PLX4720 treatment, shNFKB1 modestly impairs the rescue of pERK and of 
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viability mediated by exogenous COT.  In lines endogenously expressing COT, however, neither 
NFKB1 knockdown nor knockdown of COT itself is able to alter residual PLX4720 resistance or 
pERK following PLX4720 treatment.  Although this finding may simply be due to inadequate 
COT suppression, it is consonant with the idea intrinsic resistance is due not simply to COT 
expression, but rather to a fundamentally distinct, intrinsically resistant cellular state (of which 
COT expression happens to be one feature).  Thus, cumulatively, our core biological hypothesis 
of COT/p105 interaction has been confirmed.  Moreover, this finding providing a proof of 
principle that resistance effectors can be perturbed by targeting binding partners.  In this 
particular case, this result is unlikely to yield clinical utility both due to the modest magnitude of 
the effect and to the apparent non-requirement of COT for maintenance of intrinsic resistance.  
Nonetheless, this work illustrates a role for one component of the NF-κB pathway in regulating 
COT as a mechanism of acquired resistance.  Moreover, the principle of targeting resistance 
effectors by perturbing binding partners may prove valuable as an additional approach to 
targeting other mediators of drug resistance in cancer. 
Methods 
Constructs 
All shRNAs were in pLKO.1 vector. 
target  name  TRC identifier  target sequence 
Luciferase shLuc  TRCN0000072243 CTTCGAAATGTCCGTTCGGTT 
NFKB1 6517  TRCN0000006517 CGCCTGAATCATTCTCGATTT 
NFKB1 6518  TRCN0000006518 CCAGAGTTTACATCTGATGAT 
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NFKB1 6520  TRCN0000006520 CCTTTCCTCTACTATCCTGAA 
MAP3K8 10012  TRCN0000010012  GGGCCATTCAACCAAAGCAGA 
MAP3K8 10013  TRCN0000010013  CAAGAGCCGCAGACCTACTAA 
MAP3K8 10014  TRCN0000010014 GCGTTCTAAGTCTCTGCTGCT 
shRNA glycerol stocks were obtained through OpenBioSystems.  The p105 ΔN (494-971) 
S930A construct, in pK1 vector, was a kind gift of Bruce Horwitz [143].  The IκBα super-
repressor construct has been previously published [61, 110] and was a kind gift from David 
Barbie and Jesse Boehm.  pBABE-Puro empty vector was a gift of Cory Johannessen.  MEK1 
and COT (in pLX980-Blast-V5 or pLX304-Blast-V5 vectors) were from The RNAi Consortium. 
Cell culture 
All cells were maintained in medium supplemented with 10% FBS and 1% 
penicillin/streptomycin.  Media used were as follows: A375: RPMI.  RPMI-7951: MEM.  
OUMS23: MEM.  All cell lines were obtained from in-lab stocks. 
Primary melanocytes 
Primary melanocytes were grown in TICVA medium (Ham’s F-10 (Cellgro), 7% FBS, 1% 
penicillin/streptomycin, 2 mM glutamine (Cellgro), 100 μM IBMX, 50 ng ml−1 TPA (12-O-
tetradecanoyl-phorbol-13-acetate), 1 mM 3′,5′-cyclic AMP dibutyrate (dbcAMP; Sigma) and 
1 µM sodium vanadate).  Following lentiviral introduction of BRAFV600E, cells were switched to 
Ham’s F10 + 10% FBS.  Survival in Ham’s was used to select for BRAFV600E expressing cells as 
BRAFV600E permits survival in the absence of TICVA supplements.   
Virus infection 
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For single lentivirus infections, A375 cells were seeded in 6w plates (at 1.25e5 cpw).  The day 
after seeding, medium was changed to medium + 4 µg/mL polybrene.  125 µL of lentivirus was 
used per well.  Plates were centrifuged during infection for 30 minutes at 2250 rpm (1178 x g) at 
30 °C, followed by overnight incubation.  The subsequent day, medium was changed for fresh 
medium, and puromycin was added to a final concentration of 1 µg/mL.  Cells were selected for 
3 days before harvest.   
Infection with multiple viruses was carried out according to the following protocol: 
Day 1: seed in 6 well plate.  (RPMI-7951: 2.5e5; OUMS23: 2e5) 
Day 2: add polybrene to 4 µg/mL final and infect 1 mL retrovirus (pBABE-Puro empty vector, 
pBABE-p-IκBα SR, pBABE-puro-p105 SR) plus 125 µL shRNA lentivirus.  Plates were 
centrifuged 30 minutes at 2250 rpm (1178 x g) at 30 °C during infection. 
Day 3: morning: change to fresh medium.  Afternoon: add polybrene to 4 µg/mL final and infect 
1 mL retrovirus (pBabePuro-empty, pBp-IκBα SR, pBp-p105 SR).  For wells combining p105 
SR and shNFKB1 6517, shRNA infection was also repeated.  Plates were centrifuged 30 minutes 
at 2250 rpm (1178 x g) at 30 °C during infection. 
Day 4: change infected cells to fresh medium plus puromycin 1 µg/mL final. 
Day 7: add DMSO or PLX4720 at 1 µM. 
Day 8: Harvest (for lysates) or reseed in 96w format (for GI50 determination).  RPMI7951 was 
reseeded at 3500 cpw; A375+COT at 1750 cpw. 
For A375, protocol was as above except 1e5 cells per well were seeded 1 day earlier and an 
initial overnight infection with 125 µL LacZ or COT was performed prior to shRNA/retrovirus 
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infection.  In addition, cells were selected with both puromycin (1 mg/mL final) and blasticidin 
(10 mg/mL final). 
IL-1β stimulus 
A375 were seeded at 6.24e4/w in 12w plates.  Beginning the following day, cells were 
stimulated for indicated length of time with recombinant IL-1β (CST 8900SF) to the indicated 
final concentration, and harvested at indicated timepoints. 
Lysate harvesting 
Cells were harvested by washing 1x in PBS, applying sufficient lysis buffer to cover the well (~ 
40 uL for 12w plate, ~100 uL for 6w plate), and removing lysis buffer.  Plates were not scraped 
and lysates were not pelleted.  Cells were lysed in 1% NP40 buffer (150 mM NaCl, 50 mM Tris 
pH 7.5, 2 mM EDTA pH 8, 25 mM NaF and 1% NP-40), containing 2x EDTA-free protease 
inhibitor cocktail (Roche) and 1x phosphatase inhibitors I and II (EMD).  Lysates were 
quantitated by BCA, normalized, and denatured by boiling in sample buffer plus 20 mM DTT. 
Immunoprecipitations were performed overnight at 4 °C in 1% NP-40 lysis buffer, at 1 µg/µl 
total protein concentration, followed by binding to Protein A agarose (25 µl, 50% slurry; Pierce) 
for 2 h at 4 °C.  Beads were pelleted and washed three times in lysis buffer before elution and 
denaturing (95 °C) in 2× reduced sample buffer (Invitrogen). 
Western Blotting 
Transfers were on iBlot nitrocellulose membrane using setting P0.  Membranes were blocked 1 
hour at room temperature in LiCor blocking buffer.  Primary antibodies (1:1000 dilution unless 
otherwise indicated) were incubated overnight at 4°C in LiCor blocking buffer plus 0.1% Tween-
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20.  Secondary antibodies (1:10,000 dilution, LiCor) were incubated at room temperature for 90 
minutes in LiCor blocking buffer plus 0.1% Tween-20 and 0.1% SDS.  Imaging was on a LiCor 
Odyssey infrared imager. 
Primary antibodies were as follows (CST = Cell Signaling Technology, SCBT = Santa Cruz 
Biotechnology): BRAF (13, BD Biosciences 612375), COT (N17, SCBT sc-1717, 1:200), V5 
(Invitrogen R960-25), pMEK (41G9, CST 9154), tMEK (L38C12 CST 9122), p105 (CST 4717), 
p50 (CST 3035), IκBα (L35A5, CST 4814), MCM2 (D7G11, CST 3619), pRelA (S536, 93H1, 
CST 3033); tRelA (L8F6, CST 6956), pERK (T202/Y204, D13.14.4E, CST 4370); tERK 
(L34F12, CST 4696), GAPDH (D16H11, CST 5174),  
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CHAPTER 5.  IDENTIFYING NOVEL MELANOMA DEPENDENCIES:  
QUERYING THE NF-ΚB PATHWAY AS A POTENTIAL MELANOMA ESSENTIALITY 
 
Abstract 
Although the RAF and MEK inhibition has shown outstanding clinical promise in the 60% of 
melanomas harboring a BRAFV600 mutation, they have yet to show equivalent results in 
melanomas not harboring this mutation.  In an attempt to identify new melanoma dependencies 
not restricted by BRAF genotype, we used pooled shRNA screening data to nominate genes that 
appeared to be differentially essential across all melanoma cell lines relative to other cancers.  
Among the top hits in this analysis was MYD88, a signal transduction adapter of profound 
importance in innate immune signaling, including the NF-κB, and a recently elucidated 
dependency in several other cancer contexts.  In light of our previous interest in NF-κB in 
melanoma, we sought to query more comprehensively whether the NF-κB pathway represented a 
potential melanoma dependency.  To this end, we performed a comprehensive arrayed shRNA 
screen for essential members of the NF-κB pathway in melanoma.  This screen nominated 
additional signaling effectors around MYD88 as well as the immune-related transcription factor 
IRF3.  Subsequent validation studies revealed a link between growth inhibition and knockdown 
performance for IRF3 and a putative cross-talk between IRF3 and MYD88-dependent signal 
transduction not previously recognized.  Cumulatively, these experiments nominate the NF-κB 
pathway as an effector of potential significance and suggest a possible functional role for IRF3 in 
melanoma.  
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Introduction 
Previous chapters have considered the limitations of MAPK pathway inhibitors for BRAFV600-
mutant melanoma—namely, pre-existing intrinsic resistance and the development of acquired 
resistance.  Even with a comprehensive understanding of the mechanisms and therapeutic 
vulnerabilities of these classes of resistance, however, MAPK pathway inhibitor therapy may 
still face a fundamental limitation: although MEK inhibition has shown some early promise in 
NRAS-mutant melanoma [145], it remains primarily BRAFV600-mutant melanomas that have 
shown clinical response to MAPK pathway inhibitors.  Therefore, in melanomas that harbor 
BRAFV600 mutations as well as those that do not, MAPK pathway inhibition alone is unlikely to 
be sufficient to achieve durable control.  In principle, what is needed to overcome this limitation 
is a gene or signaling pathway, not linked to MAPK pathway genotype, and preferably 
druggable, that is essential at least in a large proportion of melanomas.  Targeting such 
vulnerabilities could illuminate therapeutic inroads for melanomas lacking BRAF/NRAS 
mutations or co-targeting opportunities in BRAF/NRAS-mutant melanomas.   
A long-standing interest in cancer biology has been the efficient identification of targets 
specifically required for tumor growth.  In the past several years, high-throughput approaches 
128 
 
have been developed to facilitate the interrogation of such dependencies.  One important 
systematic approaches involves genome-scale pooled shRNA screening.  In brief, pooled shRNA 
screening relies on the fact that cells infected with an shRNA knocking down an essential gene 
will proliferate at a reduced rate, and therefore will be outcompeted in a culture.  Each cell line is 
infected with a pooled library of lentiviruses (when this work was initiated, the library contained 
~55,000 shRNAs), at a titer to ensure ≤1 integration event per cell.  Infected cells are selected 
with puromycin and cultured for 16 populations doublings to allow lethal shRNAs to deplete.  
Genomic DNA is harvested and final shRNA abundance is deconvoluted by hybridization to a 
custom microarray.  After extensive data quality control and normalization, shRNAs 
differentially lethal to cell lines of interest relative to other cell lines are identified by 
comparative marker selection, and genes with more than one shRNA scoring are identified by a 
variety of methods. [68],[146] (Fig. 5.1) 
Pooled screening technology has found significant use in cancer.  As discovery efforts, multiple 
large-scale screening efforts have produced dependency profiles for multiple cancer cell types. 
[147], [148], [149],[150]  Broadly speaking, this approach has shown itself able to identify that 
cell lines with driver mutations in known oncogenes are generally dependent on those oncogenes 
(e.g., BRAF, KRAS, PIK3CA) [146], an important positive control for the sensitivity of this 
method.  Turned towards discovery of unknown dependencies, these screens have identified 
novel lineage essentialities such as PAX8 in ovarian cancer.[150]  This technology, however, has 
not been comprehensively leveraged in melanoma to identify novel dependencies. 
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Results 
1. A pooled shRNA screening approach to identify novel melanoma dependencies 
In order to identify candidate dependencies within melanoma not linked to BRAF genotype, we 
made use of two sources of genome-scale pooled shRNA screening data.  First, within the lab, 16 
genetically diverse melanoma short-term cultures (encompassing BRAF-mutant, NRAS-mutant, 
and BRAF/NRAS-wild-type lines) had been subjected to pooled shRNA screening (M.  Linja, 
unpublished data).  Although this dataset could in principle be analyzed on its own for genes 
essential in melanoma, such analyses tend to be dominated by genes essential in all cell types 
(e.g., ribosomal subunits) [147].  Therefore, we sought a second dataset of non-melanoma cell 
lines for comparison.  Separately, the Achilles 2 project and Broad RNAi Consortium had 
screened (at the time this study was initiated) ~40 non-melanoma cancer cell lines using the 
same shRNA library. [150]  By comparing these two datasets, we could query for genes whose 
essentiality was specific to the melanoma lineage (Fig 5.1).  Critically, because our screened 
melanoma collection included robust representation of all MAPK genotypes (BRAF-mutant, 
NRAS-mutant, and wild-type), this analysis had the potential to detect true pan-lineage 
essentialities that were independent of MAPK pathway mutational status. 
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non-melanoma melanoma 
Figure 5.1: A pooled shRNA screening approach to identify novel melanoma 
dependencies. 
Cells were infected with a pool of barcoded lentiviruses encoding an shRNA library and 
passaged for 16 population doublings to allow lethal hairpins to deplete.  The relative 
abundance of each hairpin was determined by microarray.  Gene essentialities were compared 
between melanoma and non-melanoma cell lines to identify novel putative melanoma lineage 
dependencies.  
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2. Pooled shRNA screening analysis nominates MYD88 as a novel melanoma dependency, 
suggesting a role for the NF-κB pathway 
To identify such candidate melanoma dependencies, we compared the shRNA screening data 
from our melanoma cell lines with the non-melanoma cell lines from Achilles 2, identifying 
genes preferentially depleted in melanoma relative to other cancer cell lines.  Following 
extensive quality control, normalization, and analysis, we identified MYD88 as among the genes 
most differentially essential in melanoma.  (Fig. 5.2) MYD88 is a well-characterized adapter 
protein that links Toll-like receptors (TLRs) and the interleukin 1 receptor (IL1R) to downstream 
signal transduction, most notably NF-κB.  In light of our prior investigation of the role of NF-κB 
pathway in MAPK pathway inhibitor resistance, the suggestion that NF-κB might also represent 
a melanoma lineage dependency was tantalizing.   
Moreover, MYD88 has recently been implicated as a critical signal transduction node in several 
types of cancer.  DLBCL and chronic lymphocytic leukemia harbor MYD88 activating 
mutations [151, 152].  MYD88 has also been found essential for colon cancer progression in 
ApcMin/+ mice. [153],[154]  Similar findings have been reported in other mouse models, 
particularly liver cancer. [155-157]  While the screening identification of MYD88 as 
differentially essential in melanoma was not by itself definitive, when combined with (a) the 
known role of MYD88 in other cancers; and (b) our previous interest in NF-κB signaling in 
melanoma (cf. Ch.  2, 4), it was deemed worthy of additional study.  Moreover, given the limited 
precision associated with pooled shRNA screening, we reasoned that a signal of MYD88 
essentiality might in fact be a signpost for a larger NF-κB pathway dependency.  For this reason, 
we set out to query whether the NF-κB pathway might represent a previously unrecognized 
melanoma lineage dependency. 
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Figure 5.2: Pooled shRNA screening analysis nominates MYD88 as candidate melanoma 
dependency, suggesting a role for the NF-κB pathway. 
Consensus essentiality profile (generated by ATARiS analysis) plotted for MYD88 across the 
collection of analyzed melanomas and non-melanomas.  More negative numbers indicate 
greater essentiality. 
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3. Arrayed shRNA screen nominates NF-κB pathway members, including MYD88 and 
IRF3, as candidate melanoma dependencies. 
Although our pooled screening analysis nominated MYD88 and by extension the NF-κB 
pathway as a candidate melanoma essentiality, large-scale pooled screening is by nature limited 
in its precision.  As a complementary approach, we sought to map in detail a putative melanoma 
dependency on the NF-κB pathway using an arrayed shRNA screen.  We screened ~5 shRNAs 
per gene for ~160 NF-κB pathway genes over a 7 day time course using three melanoma cell 
lines (1 BRAF-mutant, 1 NRAS-mutant, 1 BRAF/NRAS wild-type) so as to uncover 
dependencies shared across MAPK pathway genotypes.  As a control, and in collaboration with 
the Barbie and Hahn labs, 8 lung adenocarcinoma lines were also screened.  These lines provided 
a comparator group to identify shRNAs differentially toxic to melanoma but not globally toxic to 
all cancer cell lines. 
Among the hits scoring as differentially essential in melanoma was LTBR, which has been 
previously characterized as a required upstream activator of the non-canonical NF-κB pathway in 
melanoma ([74], Fig. 5.3).  Examining other top scoring hits (Table 5.1), we observed not only 
MYD88, but also numerous other members of the TLR/IL1R/MYD88 signaling module: CD14, 
a TLR4/TLR2 co-receptor; IRAK2, an immediate downstream adaptor of MYD88; Lyn, a Src-
family Ser/Thr kinase which, among other functions, has been reported to phosphorylate TLRs 
following ligand binding; and ECSIT and TAB1, two parallel signaling components proximally 
downstream of the TLR/IL1R/MYD88 module (see Fig. 5.3).  TRAF6—which bridges IRAK1/2 
to TAK1 and ECSIT—did not emerge as a top hit in this arrayed screen.  This might be due 
either to poor shRNA knockdown performance or to TRAF6 redundancy, as is observed for 
other TRAF family members.  In addition, IRF3, a transcription factor induced downstream of 
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TLR signaling, but generally considered to by MYD88-independent, emerged as the single best 
hit, showing profound and highly selective depletion in the melanoma lines.  In total, 7 out of the 
top 12 hits were related to the IL1R/TLR/MYD88/IRAK signaling module.  (Table 5.1, Fig. 
5.3). 
In light of our query hypothesis that the NF-κB pathway might contain novel melanoma 
dependencies, it seemed noteworthy that the arrayed screen revealed multiple hits around one 
annotated functional module within the NF-κB pathway.  These results suggested a preliminary 
validation of our hypothesis; moreover, they gave us a detailed gene-by-gene view of the 
components of this candidate essentiality.  We therefore initiated further functional 
characterization of these genes.   
  
Table 5.1: List of genes scoring as differentially essential in melanoma in NF-κB pathway 
arrayed shRNA screen. 
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Figure 5.3: Arrayed shRNA screen nominates NF-κB pathway members, including 
MYD88 and IRF3, as candidate melanoma dependencies. 
Top hits from arrayed shRNA validation screen (dark modules) are mapped onto various 
branches of the NF-κB pathway. 
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4. Assessment of MYD88 shRNA knockdown, pooled screening, and arrayed screening 
performance. 
Because MYD88 was the index hit in our pooled screening analysis, and because the putative 
module of dependency identified in the arrayed screen involved MYD88, we first sought to 
query the behavior of MYD88 shRNAs.  We reasoned that if MYD88 represented a legitimate 
biological dependency in melanoma, individual MYD88 shRNAs should behave consistently 
across contexts and in a manner correlated to their knockdown performance.  To test this 
hypothesis, we compared the behavior of each MYD88 shRNA in the contexts where it had so 
far been tested.  (Fig. 5.4) Surprisingly, we did not find a robust correlation between shRNAs 
that scored in the pooled analysis, the arrayed screen, and those that gave significant knockdown 
in low-throughput experiments.  Imperfect correlation between screening results and independent 
knockdown studies has been observed elsewhere (unpublished Achilles screening data) and 
might relate to procedural differences between arrayed and pooled screens or “off-target” effects 
of individual shRNAs.  Thus, the aggregate results of the arrayed screen and knockdown data 
generally supported the notion that an NF-κB signaling module might comprise a melanoma 
dependency, but the relative importance of MYD88 as a central node remained unclear. 
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Figure 5.4: Assessment of MYD88 shRNA knockdown, pooled screening, and arrayed 
screening performance. 
Representative knockdown performance of the MYD88 shRNAs, correlated with performance 
in the pooled and arrayed screens. 
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5. Growth inhibitory effects of MYD88 shRNAs in melanoma and non-melanoma cell lines 
Because of the imperfect correlation between which shRNAs scored in the pooled screening 
analysis and which scored in the arrayed screen, it remained unclear which MYD88 shRNAs 
actually impaired the growth of melanoma cell lines.  To clarify this question, we expressed all 5 
available MYD88 shRNAs in the three melanoma cell lines used for the screen and performed 7-
day growth inhibitory studies.  (Fig. 5.5A) We found that the majority of the MYD88 shRNAs 
did confer a growth deficit, typically in the range of 50%.  In particular, this was true of those 
shRNAs that scored in the pooled screening analysis as well as the arrayed screen.  This finding 
confirmed that knockdown of MYD88 can confer a growth deficit on melanoma cell lines.  
Moreover a 50% growth deficit over a 7-day timecourse might result in a significant fitness 
disadvantage under pooled shRNA screening conditions (i.e., 16 population doublings) 
We also sought to understand the extent to which these growth inhibitory effects were specific to 
melanoma.  To address this question, we again expressed all 5 MYD88 shRNAs, but this time in 
a panel of 4 lung adenocarcinoma cell lines used in the control arm of the arrayed screen.  (Fig. 
5.5B) In many cases, we found that MYD88 shRNAs impaired the growth of non-melanoma cell 
lines to a comparable degree as they impaired melanoma cell lines.  Moreover, no clear 
correlation was observed between growth inhibitory effects, in either melanoma or non-
melanoma cell lines, and knockdown performance at the protein level (compare Fig. 5.4).  This 
finding suggests that, while knockdown of MYD88 does impair the growth of melanoma cell 
lines, this phenotype may be due either to a dependency shared between melanoma and non-
melanoma lines, or, at least in part, to non-specific growth inhibitor effects that are also shared 
with non-melanoma cell lines.   
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Figure 5.5: Growth inhibitory effects of MYD88 shRNAs in melanoma and non-
melanoma cell lines. 
Growth inhibitory effects of 5 MYD88 shRNAs on melanoma (a) and non-melanoma (b) cell 
lines from the arrayed screen.  
(a)  (b)  
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6. Correlation of arrayed screening and knockdown performance for selected targets.   
Although the correlation between knockdown and growth effects was imperfect for MYD88 
shRNAs, our arrayed screen nominated a broader functional module of which MYD88 was just 
one member.  We therefore sought to validate more comprehensively this module as a whole by 
querying a relationship between protein-level knockdown and screening phenotype (Fig 5.6A). 
We reasoned that, if shRNAs scoring well in the arrayed screen (i.e., differentially lethal to 
melanoma vs. non-melanoma cells) also showed strong knockdown, the growth-inhibitory 
effects of such shRNAs were more likely due to “on-target” effects.  In contrast, poor correlation 
between growth inhibition and knockdown would suggest that growth inhibition might be due to 
off-target toxicity. (Fig 5.6B)  Because the arrayed screening analysis nominated hits 
differentially lethal in melanoma vs. non-melanoma cell lines, we used this (rather than absolute 
lethality in melanoma cell lines) as the metric for loss of viability.  To test the hypothesis that 
differential shRNA lethality for our hits would correlate with protein-level knockdown, we 
infected A375 cells with shRNAs for the selected hits, harvested lysates, quantitated knockdown 
for each target of interest relative to actin loading control, and correlated that knockdown with 
the screening performance of each shRNA.  Results are graphed in Fig. 5.6C.   
As a negative control, we included TRAF6 (Fig. 5.6C, bottom right), a gene whose function has 
been linked to MYD88 but that did not did not score in either the pooled or arrayed screens.  
Consistent with this result, we found no correlation for TRAF6 between knockdown 
effectiveness and screening Z score.   
We delineated several possible results.  Strong knockdown with differential lethality (in 
melanoma vs. non-melanoma) (bottom left quadrant) is consistent with on-target killing; 
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conversely, weak knockdown with poor differential lethality (upper right quadrant) is consistent 
with an ineffective shRNA.  On the other hand, strong knockdown with poor differential lethality 
(bottom right quadrant) is consistent either with off-target toxicity across cell lines, or with non-
essentiality of the gene in melanoma; conversely, weak knockdown with strong differential 
lethality (upper left quadrant) is consistent with off-target toxicity specific to melanoma.  We 
were therefore most interested in genes with multiple shRNAs scoring in the lower left quadrant. 
Applying this framework to the hits, we noted that many of our hits had at least some shRNAs 
with excellent knockdown (e.g., IRAK2); however, these were not always among the most 
differentially lethal.  Rather, some of the most differentially lethal shRNAs displayed relatively 
poor knockdown (e.g., IRAK2, TAB1, ECSIT).  This result suggests that, for at least some of 
these shRNAs, observed differential lethality in melanoma might be due to off-target effects.   
A notable exception to this trend, however, was seen in shRNAs targeting IRF3, the top single 
hit in the arrayed screen.  Here, the shRNAs most differentially lethal were also among those 
achieving best knockdown.  Although two shRNAs also gave >50% knockdown without 
differential lethality, this could be due to off-target toxicity of these shRNAs common across cell 
lines.  For this reason, and because IRF3 was the strongest hit from the arrayed shRNA screen, 
we sought to functionally query the IRF3 signaling in melanoma.   
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Figure 5.6:  Correlation of arrayed screening and knockdown performance for selected 
targets. 
(a) Example of 96w knockdown validation Western blot.   
(b) Schematic of graph plotting percent expression remaining relative to screening Z score.  
Lower left quadrant is consistent with on-target killing.  Upper left quadrant is consistent with 
off-target toxicity specific to melanoma.  Upper right quadrant is consistent with ineffective 
shRNAs.  Lower right quadrant is consistent with either off-target toxicity across all cell lines, 
or non-essentiality of the targeted gene in melanoma. 
(c)  Plots of percent expression remaining and screening Z score for every screened hairpin 
for the indicated 8 genes. 
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7. Functional relationships among MYD88, IRF3, and NF-κB pathway. 
Our cumulative results identified a putative module of dependency within the NF-κB pathway 
around MYD88 and a particular validated dependency on IRF3.  Historically, these components 
have been classified in separate arms of the NF-κB pathway (Fig. 5.3), with hits around MYD88 
involved in transducing phosphoactivation of the RelA transcription factor in response to ligands 
such as LPS and IL-1β, whereas IRF3 is itself a downstream transcription factor, activated in a 
MYD88-independent fashion by viral antigens (e.g., dsRNA).  Given the potential functional 
relevance of these modules in melanoma but the lack of a known functional relationship between 
them, we sought to query whether signaling cross-talk might exist in this context.  A functional 
relationship between these two genes could explain why both of them were identified as putative 
melanoma dependencies. 
To test this, we queried signaling following knockdown of MYD88 and IRF3, using 3 
independent shRNAs for each gene.  Because pIRF3 is the readout for IRF3 activation, however, 
we needed to perturb an additional component in the IRF3 signaling pathway to ascertain 
signaling effects on IRF3.  Therefore, we also knocked down TBK1, a kinase essential for TLR 
signaling to IRF3.  After these perturbations, we then left cells untreated (Fig. 5.7, left panel) or 
perturbed them with IL-1β (Fig. 5.7, middle panel), which should activate signaling through 
MYD88 but not IRF3, or with poly(I:C), an artificial TLR3 ligand (Fig. 5.7, right panel), which 
should lead to IRF3 activation in a MYD88-independent manner.  As an additional control, we 
included an uninfected control in the unstimulated panel (right-most lane, left panel).  We 
observed no signaling differences at baseline between the uninfected control and the shLuc 
negative control shRNA, suggesting that neither lentiviral infection or shRNA expression itself 
was perturbing these innate immune signaling pathways. 
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Figure 5.7:  Functional relationships among MYD88, IRF3, and NF-κB pathway. 
(a) A375 cells were infected with shRNAs as indicated, selected 3 days with puromycin, then 
left untreated or stimulated with IL-1β (25 ng/mL) or poly(I:C) (1000 ng).  In addition to 
TBK1 shRNAs, TBK1 inhibitor MRT67307 (5 µM) was used as a second TBK1 loss-of-
function reagent.   Activation of downstream pathways was assessed by Western blot.  Orange 
boxes indicate knockdown of shRNA targets; blue boxes indicate impairment of signaling 
directly downstream of either IL-1β or poly(I:C) stimulus; green boxes indicate putative 
cross-talk between these pathways.  
(b) Schematic of pathway crosstalk queried in this experiment.  
(b)  
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First, we confirmed adequate knockdown of targets (orange boxes).  Next, we queried the effect 
of knockdown of these targets in the unstimulated state.  At baseline, knockdown of MYD88 or 
IRF3 had no obvious effects on phosphorylation of RelA, a commonly used marker of NF-κB 
pathway activity, or on phosphorylation of ERK.  One mark of IRF3 activation is its 
phosphorylation at S396[158]; however, we observed no pIRF3 at baseline.  This finding may 
imply that basal IRF3 activity in melanoma is simply below our detection limit, or that baseline 
IRF3 activity may operate through a mechanism of activation other than phosphorylation of the 
site queried by our antibody. 
Next, we assessed whether “canonical” signaling downstream of shRNA targets was impaired by 
knockdown (Fig. 5.7, blue boxes).  Indeed, shMYD88 abrogated IL-1β-induced increase in 
pRelA (center panel), and shTBK1 decreased poly(I:C)-mediated pIRF3 (right panel).  These 
findings demonstrate that both of the signaling modules nominated by our screen are competent 
to transduce signals in melanoma—an important demonstration of their potential functional role 
in this lineage.  Together, these experiments confirmed that we achieved (a) adequate stimulation 
of signaling through the relevant modules and (b) adequate knockdown of our targets at both a 
protein level and functional level.  This experiment was therefore powered to detect cross-talk 
between these pathways or its abrogation. 
We next queried whether any cross-talk might be detected between the canonical NF-κB 
(including MYD88) and IRF3 signaling modules (Fig. 5.7, green boxes).  Despite robust 
increase in pRelA, IL-1B did not lead to discernible IRF3 phosphorylation (center panel), 
implying that signaling through MYD88 may not be sufficient to activate pIRF3.  Further, 
shMYD88 did not impair poly(I:C)-mediated pIRF3 (right panel), arguing that MYD88 is not 
necessary for activation of pIRF3 at least by poly(I:C) and at the levels of suppression achieved 
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in these experiments.  We thus concluded that signaling through MYD88 may not contribute to 
IRF3 activity. 
Conversely, we also assessed cross-talk from the IRF3 module to the MYD88 module.  First, we 
queried whether poly(I:C) was sufficient to activate mediators typically considered downstream 
of MYD88.  Indeed, we found that poly(I:C), in addition to activation of pIRF3, conferred robust 
RelA phosphorylation (Fig. 5.7, right panel).  This suggests that an upstream stimulus through 
TLR3 can signal not only to IRF3 but also to the NF-κB effector module.  Interestingly, this 
increase in pRelA was not abrogated by TBK1 knockdown, raising the possibility that cross-talk 
may proceed through other proximal signaling intermediates.  Although MYD88 might 
conceivably represent one such intermediate, its involvement appears unlikely because 
shMYD88 also did not reduce poly(I:C)-induced RelA phosphorylation.  Thus, we conclude that 
while poly(I:C) is sufficient to signal into the canonical NF-κB module, MYD88 may not be 
required for this cross-talk.   
Having established that signals through the TBK1/IRF3 module were sufficient to activate 
pRelA, we next asked whether the TBK1/IRF3 signaling module was necessary for IL-1β-
induced RelA phosphorylation.  Surprisingly, we found that shIRF3 and shTBK1 reduced IL-1β-
induced pRelA to an extent comparable to that achieved by shMYD88 (Fig. 5.7, center panel).  It 
is possible that, in the case of TBK1, this phenomenon might occur due to cross-talk between 
TBK1-containing and MYD88-containing complexes.  (Note, for example, the upregulation of 
MYD88 upon TBK1 knockdown, left panel.) It is less clear however, how IRF3—as a putatively 
downstream transcription factor—might be required for MYD88-dependent signal transduction.  
Nonetheless, these perturbational experiments suggest that the TBK1/IRF3 module may be 
necessary for canonical NF-κB signaling in melanoma. 
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Discussion and future directions 
Nomination of NF-κB modules as candidate melanoma dependencies 
Cumulatively, this study leveraged a particular analysis of existing pooled shRNA screening 
datasets to design and execute an arrayed follow-up screen.  Furthermore, validation of hits was 
achieved by knockdown confirmation and by functionally querying the nominated signaling 
pathways.   
Pooled shRNA screening analysis initially nominated MYD88 as one component of a potential 
melanoma lineage dependency.  A subsequent arrayed shRNA screen identified IRF3, as well as 
MYD88 and other genes in close functional relationship to it, as candidate melanoma 
dependencies.  The putative module of dependency around MYD88 appeared to involve the 
canonical NF-κB pathway.  Although subsequent validation revealed an imperfect correlation 
shRNA knockdown and screening performance for some hits, including MYD88, such disparity 
is not entirely unexpected given the different formats used (pooled, arrayed, and low-
throughput), the potential for off-target shRNA effects, and the different effects of shRNAs 
within specific cellular contexts.   
Moreover, our arrayed screen nominated IRF3, a transcription factor critical for antiviral 
response but historically placed in a separate, MYD88-independent NF-κB pathway, as another 
candidate melanoma dependency.  Not only was IRF3 the top hit in our arrayed screen for 
differential lethality in melanoma, it also showed the best knockdown/lethality correlation.  This 
result is novel for melanoma, as these modules have not previously been suggested as melanoma 
dependencies.  In particular, IRF3, given the strength of its phenotype and knockdown 
correlation, appears worthy of further investigation to characterize the mechanism of its 
dependency in melanoma.   
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Subsequent work has assessed the functional importance of these putative essentialities.  
Although demonstrating their activity at baseline proved challenging, we have shown that the 
signaling modules around MYD88 and IRF3 can be active in melanoma following stimulus, a 
finding that reaffirms these candidate dependencies can be functional signaling modules in 
melanoma.  Second, we queried cross-talk between the two modules.  We did not uncover any 
evidence of that the MYD88 module is necessary or sufficient for signaling to IRF3.  We did, 
however, find that poly(I:C) mediated stimulus of IRF3 was also sufficient to activate the 
canonical NF-κB pathway.  More striking, both IRF3 and its upstream kinase TBK1 appeared to 
be essential for optimum IL-1β signaling through MYD88.  This result is novel and unexpected, 
not only in melanoma biology, but even in the innate immune context, where MYD88 and IRF3 
have historically been considered a part of separate pathways. 
Future directions for shRNA screening in melanoma 
To the extent that MYD88 and/or IRF3 represent authentic melanoma dependencies, cross-talk 
between them implies the possibility of new signaling effects that could be determinants of this 
dependency.  The nature of such signals, as well as their relevance to melanoma survival, 
remains obscure.  Thus, future efforts—in addition to extending the initially promising validation 
of IRF3 as a melanoma dependency—will need to take into account the challenge of 
characterizing the downstream signal mediated by IRF3, and how that signal intersects with both 
the MYD88 module and with melanoma survival.  This as-yet uncharacterized signaling 
pathway, being novel both in its mechanistic details and in its status as a melanoma dependency, 
is a promising target for future investigation. 
In addition to pursuit of specific questions around IRF3 and MYD88, another avenue for further 
investigation is extending the analysis of shRNA screening in melanoma.  Of note, our current 
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analysis did not attempt to segregate melanomas by expression class (MITF or NF-κB), as no 
intrinsically resistant, high-NF-κB lines were present in the initial pooled screening dataset.  In 
light of the now understood importance of the high NF-κB class, and its profoundly different 
biology, an important avenue for further investigation will be querying this class for unique 
essentialities potentially not shared by other high-MITF melanoma.  This could take place either 
at the genome-scale level, using pooled screening, or in a more targeted fashion using the NF-κB 
arrayed screening shRNA set that we have curated. 
Although we have carried out an initial analysis for differential dependency in melanoma, there 
are many other resources that can be leveraged to ask additional questions.  For example, using 
both shRNA screening and copy number data could allow one to look for genes both amplified 
and essential in melanoma; a similar analysis with expression data could identify genes both 
overexpressed and essential in melanoma.  The potential to integrate other data sources offers 
many additional lenses through when to view shRNA screening data which more sharply focus 
the hypothesis being queried in the shRNA analysis.  In addition, use of two orthogonal, 
independent data sources (e.g., pooled screening and copy number data) is a powerful way to 
filter out the false positives of either approach.  Therefore, a systematic approach should be 
undertaken to (a) catalog what data sources are currently available for the melanoma lineage, (b) 
comprehensively delineate what biological questions can be asked by the appropriate intersection 
of these data sources, and (c) perform the identified analyses in order to search for any 
particularly noteworthy hits worthy of further investigation. 
Conclusion 
Taken together, the data in this aim nominate two novel candidate dependencies in melanoma: a 
module around MYD88, and IRF3.  This screen thus provides evidence for the essentiality of at 
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least some signaling nodes in the NF-κB pathway in melanoma.  However, our data also suggest 
that, in melanoma, the signaling circuitry within and/or between these canonically MYD88-
dependent and MYD88-independent modules may not be as compartmentalized as thought.  
Rather, the IRF3/ “MYD88-independent” module appears to be both necessary and sufficient to 
effect signaling through the module around MYD88.  This finding sets the stage for further 
functional investigation as well as suggests broad strategies for the future analysis of pooled 
screening data in melanoma. 
 
Methods 
Pooled screening data analysis 
Raw microarray .CEL files were normalized, background corrected, probeset-averaged, and log-
transformed in dChip.  Outlier replicates within a cell line were filtered on the basis of MvA 
plots.  Remaining replicates were collapsed to a single value and normalized to the concentration 
of each shRNA in the initial plasmid pool using a metric that penalizes shRNAs with large 
variation in the initial plasmid pool (modified log fold change).  The resulting score distributions 
was normalized using the PMAD metric.  Modules for all normalization steps following dChip 
are available on GenePattern.  Finally, following normalization, genes were analyzed in one of 
two ways.  First, essentiality scores for each gene in each cell line were calculated using the 
ATARiS tool [146]; differential essentiality was then calculated on the basis of fold change 
between melanoma and non-melanoma.  Second, using the RIGER method, individual shRNAs 
were compared between the melanoma and non-melanoma classes on the basis of log fold 
change.  Subsequently, this ranked list of shRNAs was collapsed to a ranked list of genes by 
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weighting the best shRNA 25% (to account for the possibility of it being off-target) and the 
second-best shRNA 75%. 
Cell culture 
All cells were maintained in medium supplemented with 10% FBS and 1% 
penicillin/streptomycin.  The following cell lines were maintained in RPMI-1640: A375, 
Skmel30, Wm3682.  A375, Skmel30, and Wm3682 were obtained from in-lab stocks; H1975, 
H1437, H522, and A549 were obtained from David Barbie.   
Arrayed screening 
shRNA-bearing lentiviruses for the screening set were produced by The RNAi Consortium 
(Broad Institute) and re-arrayed into 384w format.  A375 cells were seeded at 400 cpw, 
SKMEL30 at 900 cpw, and WM3682 at 600 cpw.  Each plate included empty well, empty 
vector, and irrelevant shRNA controls for subsequent data quality control.  24 hours after cell 
plating, media was changed to include 4 μg/μL polybrene, and cells were infected with 1-1.5 μL 
virus followed by a 30 min spin at 2250 rpm (1178 x g) at 30 °C.  24 hours after infection, 
selection was begun with 1 μg/μL puromycin.  Cells were grown 5 days, and viability was 
determined by CellTiter-Glo assay.  Cell lines were screened in quadruplicate; 3 replicates were 
selected with puromycin, and 1 replicate was not selected with puromycin in order to calculate 
infection efficiency.  shRNAs were filtered by infection efficiency, and data were normalized 
between plates by converting raw luminescence values to robust Z scores.  In order to go from 
ranked shRNAs to a ranked gene list, we used a weighted average of the ranks of the two best 
shRNAs for a given gene, with 25% weight on the best-scoring shRNA (to account for the 
possibility of that shRNA having an off-target effect) and 75% weight on the second-best 
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shRNA.  The inclusion of 2 shRNAs reflects the finding that, for this library, out of 5 shRNAs 
against a gene, typically 2-3 give good knockdown.   
Medium-throughput knockdown validation 
For validation of knockdown/screening correlation, shRNAs targeting genes of interest were re-
arrayed into a single 96-well plate.  A375 cells were seeded into 96-well plates.  The following 
day, cells were changed to medium containing 4 µg/mL puromycin, infected with 1.5 µL shRNA 
lentivirus per well, and spin infected for 60 minutes at 2250 rpm (1178 x g) at 30 °C.  Medium 
was immediately changed following infection.  The next day, puromycin was added to a 
concentration to 1 µg/mL final.  After 3 days of selection, lysates were harvested using a multi-
channel pipette.  To increase lysate concentration, lysates were pooled from 3 replicate plates.   
shRNA growth inhibition 
For shRNA growth experiments, cell lines were infected in 6 well format followed by 3 days 
selection with puromycin (1 µg/mL final).  Cells were then reseeded into 96 well format at 1000-
3000 cpw.  7 days after seeding, viability was read out using CellTiter-Glo and compared to 
shLuc. 
IRF3/MYD88 cross-talk 
For shRNA knockdown followed by stimulus, A375 cells were seeded at 7.4e4 cpw in a 12-well 
plate.  The next day, following addition of polybrene to 4 µg/mL final, cells were spin infected at 
2250 rpm (1178 x g) at 30 °C for 30 minutes with 40-60 µL virus per well.  Beginning the next 
day, cells were selected for 2 days with 1 µg/mL puromycin.  After 2 days of selection, medium 
was removed, cells were washed once in PBS to remove dead cells (due to shMYD88 and 
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shIRF3 lethality), and cells were returned to medium plus puromycin, with or without 5 µM 
MRT 67307.  The next day, cells were treated for 90 minutes with IL-1β (100 ng/mL, Cell 
Signaling Technologies) or transfected (FuGene 6, Roche) with poly(I:C) (1000 ng, Invivogen).   
Lysate harvesting 
Cells were harvested by washing 1x in PBS, applying sufficient lysis buffer to cover the well (~ 
40 uL for 12w plate, ~100 uL for 6w plate, ~250 µL for 10 cm plate), and removing lysis buffer.  
Plates were not scraped and lysates were not pelleted.  Cells were lysed in 1% NP40 buffer 
(150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA pH 8, 25 mM NaF and 1% NP-40), containing 
2x EDTA-free protease inhibitor cocktail (Roche) and 1x phosphatase inhibitors I and II (EMD).  
Lysates were quantitated by BCA, normalized, and denatured by boiling in sample buffer plus 20 
mM DTT. 
Western blotting 
All gels to be probed for MYD88 were transferred to Immobilon-FL PVDF membranes.  
Membranes were blocked 1 hour at room temperature in LiCor blocking buffer.  Primary 
antibodies (1:1000 dilution unless otherwise indicated) were incubated overnight at 4°C in LiCor 
blocking buffer plus 0.1% Tween-20.  Secondary antibodies (1:10,000 dilution, LiCor) were 
incubated at room temperature for 90 minutes in LiCor blocking buffer plus 0.1% Tween-20 and 
0.1% SDS.  Imaging was on a LiCor Odyssey infrared imager. 
The following primary antibodies were used.  CST = Cell Signaling Technology, SCBT = Santa 
Cruz Biotechnology.  MYD88 (D80F5.  CST 4283), pIRF3 (4D4G, CST 4947), IRF3 (D83B9, 
CST 4302), TBK1 (D1B4, CST 3504), pTBK1 (D52C2, CST 5483), CSNK2A1 (CST 2656), 
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ECSIT (Abcam ab-21288), IKBKE (72B587, SCBT sc-52931), TAB1 (C25E9, CST 3226), 
IRAK2 (CST 4367), TRAF6 (CST 4743). 
shRNAs 
All shRNAs were in pLKO.1 vector. 
target  name  TRC identifier  target sequence 
Luciferase shLuc  TRCN0000072243 CTTCGAAATGTCCGTTCGGTT 
MYD88 1 / 8024 TRCN0000008024 CCACCAACTTTGTACCTTGAT 
MYD88 8025  TRCN0000008025 GCAGAGCAAGGAATGTGACTT 
MYD88 8026  TRCN0000008026 ACAGACAAACTATCGACTGAA 
MYD88 2 / 8027 TRCN0000008027 CATCAAGTACAAGGCAATGAA 
MYD88 3 / 11223 TRCN0000011223 CCTGTCTCTGTTCTTGAACGT 
IRF3  1  TRCN0000005921 GCCAACCTGGAAGAGGAATTT 
IRF3  2  TRCN0000005922 CGCAAAGAAGGGTTGCGTTTA 
IRF3  3  TRCN0000005923 GATCTGATTACCTTCACGGAA 
shTBK1 D1, D2, and D3 were a gift from David Barbie. 
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CHAPTER 6.  CONCLUSIONS AND FUTURE DIRECTIONS 
Approach to the problem 
A guiding theme of this dissertation has been the limits of currently available MAPK pathway 
therapeutics in melanoma.  Although BRAFV600 mutations have emerged as a powerful predictor 
of response to MAPK pathway inhibition, there remain three limitations to this therapeutic 
approach.  First, not all BRAFV600-mutant melanomas respond to MAPK pathway inhibition 
(intrinsic resistance).  Second, of those that do respond, most eventually relapse (acquired 
resistance).  Third, for both those melanomas harboring BRAFV600 mutations as well as those 
lacking them, durable control is likely to require the identification of therapeutically tractable 
vulnerabilities beyond the MAPK pathway.  We have endeavored to probe these challenges by 
identifying molecular determinants of intrinsic resistance, investigating ways to perturb 
mediators of acquired resistance, and screening for melanoma dependencies not linked to MAPK 
pathway mutational status. 
In addressing the problem of intrinsic resistance, we discovered that many BRAFV600-mutant 
melanomas intrinsically resistant to MAPK pathway inhibition exhibit a transcriptional state 
distinct from those sensitive to MAPK pathway inhibition.  Intriguingly, this cellular state is 
characterized by low expression of the melanocyte lineage transcription factor MITF (and its 
target genes), but activation of the NF-κB pathway and expression of marker genes including the 
receptor tyrosine kinase AXL.  This high-NF-κB state can arise in melanocytes secondary to 
aberrant MAPK activation by BRAFV600E, but its induction can be at least partially antagonized 
by dysregulated MITF.  In established melanoma cells, these states remain plastic and mutually 
antagonistic.   
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The gene encoding the AXL receptor tyrosine kinase, which was strongly associated with the 
intrinsically resistant state, was previously identified as an effector of acquired MAPK pathway 
inhibitor resistance.  We validated this observation, but also demonstrated that several 
intrinsically resistant lines do not depend upon AXL for maintenance of intrinsic resistance.  
Thus, AXL expression is sufficient but not necessary for resistance to RAF/MEK inhibitors.  
This finding is consistent (a) with the extensive expression differences we observed between 
intrinsic sensitivity and resistance, which encompass many genes in addition to AXL, and (b) the 
fact that AXL was induced by NF-κB activation, implying that, while it may be one downstream 
effector of intrinsic resistance, it is not the master regulator of this phenotype. 
Our studies of acquired resistance focused on the role of NFKB1 p105 in modulating the stability 
of COT, a known resistance effector.  This approach, which was hypothesis-driven rather than 
unbiased, was motivated by two considerations: (1) the notion that a mediator of acquired 
resistance could be regulated by NF-κB, and (2) the current paucity of potent and selective small 
molecule COT inhibitors.  We observed that suppression of p105 (by shRNA knockdown) was 
indeed an effective means to reduce COT protein levels in melanoma cells.  Following 
exogenous COT expression, where COT was known to be the only active resistance effector, 
p105 perturbation was sufficient to impair (albeit to a modest degree) COT-mediated rescue of 
pERK and viability following PLX4720 treatment.  However, in intrinsically resistant cell lines 
expressing COT, even robust suppression of COT did not affect pERK or viability following 
PLX4720 treatment.  This result is consonant with our observations from the preceding chapters 
that the phenotype of intrinsic resistance is broader than a single resistance effector, and 
therefore, that perturbing individual effectors appears not to sensitize melanoma cells to MAPK 
pathway inhibitors.   
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Finally, to address the need to discover additional melanoma dependencies, we analyzed large-
scale pooled shRNA screening data generated across a collection of melanoma and non-
melanoma cell lines.  An informative observation from the primary pooled shRNA screen was 
that MYD88, an adaptor protein required for signal transduction into the NF-κB pathway, 
emerged as putatively essential in melanoma.  This finding, noteworthy in light of our prior 
interest in NF-κB, led us to perform a follow-up arrayed shRNA screen to characterize NF-κB 
pathway dependencies in melanoma.  This screen nominated two signaling modules: one, 
centered around MYD88, that implicated signal transduction to the canonical NF-κB 
transcription factor RelA; and a second, historically considered MYD88-independent, consisting 
of the IRF3 transcription factor.  Subsequent mechanistic studies suggested a role for IRF3 in 
signal transduction through a MYD88-dependent signaling module in melanoma cells.  While 
the nature of the contributions by IRF3 to melanoma signaling and dependency remains to be 
more fully elucidated, this work has nominated both IRF3 and the module around MYD88 as 
promising targets within the NF-κB pathway for future investigation. 
Emergence of NF-κB as a common theme in melanoma 
A unifying finding from these investigations was the emergence of the NF-κB pathway as a 
common theme in melanoma.  Although prior studies have examined the NF-κB pathway in 
melanoma (see Introduction), this pathway has not been a major focus of the melanoma field to 
date.   
This work has highlighted several reasons for renewed interest in NF-κB signaling in melanoma.  
We have shown that COT, an effector of acquired MAPK pathway inhibitor resistance, is 
regulated in melanoma by binding to p105 NFKB1.  Through shRNA screening, we nominated 
two modules within the NF-κB pathway as putative melanoma dependencies.  Last, we have 
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shown that intrinsic resistance to MAPK pathway inhibitor in BRAFV600 mutant melanoma is 
associated with a high-NF-κB/low-MITF transcriptional state, and that reciprocity between 
MITF and NF-κB may underlie the phenomenon of intrinsic resistance. 
Questions for future investigation 
Perhaps the broadest question is whether the multiple observations involving the NF-κB pathway 
are merely coincidental, or whether they reflect a unifying biological process contributing to 
melanoma initiation and/or progression.  Several lines of evidence suggest an underlying 
connectivity amongst these observations.  For example, although the we have shown protein 
stability of the resistance effector COT to be modulated by NFKB1 p105, the fact that the only 
COT-expressing BRAFV600E melanoma cell line belonged to the high NF-κB subclass suggests 
that COT transcription also may be linked to the high-NF-κB state.  Another line of evidence 
linking these observations emerged when sensitive cell lines were cultured to resistance in 
PLX4720; here, one of the resistant clones that emerged had not only transitioned to the high-
NF-κB state, but also gained COT overexpression.  Thus, in addition to p105-mediated 
regulation of COT protein stability, the high-NF-κB state may be linked to COT expression.   
Another line of evidence for a possible linkage between the high-NF-κB state and COT 
dysregulation comes from studies of non-transformed human melanocytes.  At baseline, these 
melanocytes express COT, but upon introduction of BRAFV600E and subsequent induction of NF-
κB, they lose COT expression (Fig. 4.1).  In this case, the context of COT expression is opposite 
from that observed in melanoma cell lines: in melanocytes, COT is expressed in the high-MITF 
state before BRAFV600E introduction, whereas in melanoma cell lines it is expressed in the low-
MITF state associated with intrinsic resistance.  Thus, although the directionality of COT 
regulation appears to differ between these two contexts, it appears that in both cases, gain or loss 
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of COT expression is not a single-gene perturbation, but rather one component of a broader shift 
in cellular state linked to NF-κB activation.   
More generally, the MITF-low/NF-κB-high cellular state in melanoma may comprise an 
important area of future investigation.  As discussed in Chapter 2, there is much mechanistic 
detail still to uncover about the origin of this state.  How does BRAFV600E induce NF-κB 
activation, AXL expression, and MITF suppression? How do most melanomas maintain MITF 
expression in the setting of BRAFV600E mutation?  Moreover, we have characterized that 
originally drug-sensitive, high-MITF cells can transition to the high-NF-κB state during 
acquisition of resistance, regardless of which individual resistance effectors (e.g., COT, AXL, 
p61 BRAF) they express.  Thus, is this high-NF-κB state, in addition to being a feature of 
intrinsic resistance, also a unifying feature of acquired resistance? If so, and if we can 
characterize the mediators of the transition into this state during MAPK pathway inhibitor 
therapy, it is possible that this transition could be blocked or delayed therapeutically.  Such an 
intervention would potentially extend the durability of response to MAPK pathway inhibitors in 
BRAFV600-mutant melanoma by forestalling acquisition of resistance. 
Another question pertains to how the high NF-κB state is induced by BRAFV600E in melanocytes, 
yet marks resistance to MAPK pathway inhibition in melanoma.  Why, fundamentally, are the 
high NF-κB melanomas resistant to MAPK pathway inhibition? Given the low levels in these 
melanomas of expression and activity of MITF, the canonical master regulator of the melanocyte 
lineage, can the high-NF-κB state be conceptualized as an alternative cellular fate decision? If so, 
does it correspond to a previous developmental state in the natural history of melanocytes or the 
neural crest?  
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The fact that melanomas intrinsically resistant to MAPK pathway inhibition exhibit a distinct 
transcriptional state carries with it obvious potential therapeutic implications.  Indeed, we have 
shown initial clinical data that pre-treatment AXL expression (representing high-NF-κB cellular 
state) predicts a shorter response to MAPK pathway inhibition.  While this finding suggests the 
prognostic importance of these transcriptional states, it comes with two caveats.  First, this 
finding does not suggest excluding patients with AXL-positive melanoma from MAPK pathway 
inhibitor therapy, as some such patients experienced progression-free survival of up to 12 months 
on dabrafenib + trametinib treatment.  Second, the fact that some AXL-positive patients 
experienced relatively durable responses to MAPK pathway inhibition suggests the need for a 
more refined signature of intrinsic resistance capable of more reliably guiding clinical prognosis. 
Beyond MAPK pathway inhibitors, the other class of targeted therapeutics currently approved or 
in late-phase trials for melanoma consists of drugs such as ipilimumab or anti-PD1 antibodies 
that block immune checkpoint mechanisms.  Interestingly, a recent report describes that TNFα-
mediated downregulation of melanoma antigens leads to resistance to resistance to adoptive 
cytotoxic T cell transfer therapy. [159]  Although the connection was not discussed in this report, 
these melanoma antigens are primarily MITF target genes (e.g., gp100/PMEL/SILV; cf. Ch. 2; 
[160]).  Conceivably, a similar mechanism of resistance may operate for ipilimumab and 
associated therapies as well, which likely rely on immune recognition of melanoma antigens.  
Thus, melanomas that are intrinsically resistant to MAPK pathway inhibition and express low 
levels of MITF and its melanoma antigen target genes may prove resistant to immunomodulatory 
therapies as well. 
Given the paucity of current therapeutic options for melanomas that are intrinsically resistant to 
RAF/MEK inhibition, a critical direction for future investigation will be the elucidation of 
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tractable therapeutic vulnerabilities in this set of melanomas.  Here, two options present 
themselves: attempting to confer sensitivity to MAPK pathway inhibitors, and finding novel 
vulnerabilities outside of the MAPK pathway.  As detailed in Chapters 3 and 4, attempts to 
sensitize intrinsically resistant cells to MAPK pathway inhibitors by impairing the function of 
individual resistance effectors (COT and AXL) proved disappointing, at least in vitro.  However, 
it is possible that other perturbations exist which would render these cells sensitive to MAPK 
pathway inhibition; these targets could be discovered either through computational approaches or 
through shRNA screens for sensitization to MAPK pathway inhibitors, as detailed in Chapter 5. 
In addition to such efforts to sensitize intrinsically resistant melanomas to MAPK pathway 
inhibition, shRNA screening efforts such as those detailed in Chapter 5 may offer a path to 
identify novel candidate dependencies outside of the MAPK pathway.  Such dependencies, in 
principle, might be either (a) shared across all melanomas, regardless of MITF expression status 
or (b) unique to this high-NF-κB melanoma subclass.  Indeed, the nomination of a candidate NF-
κB dependency across melanomas (involving MYD88 and/or IRF3) may suggest that, while the 
high-NF-κB subclass exhibits a prominent NF-κB-driven phenotype, this pathway may be 
operant in other genetic or molecular subtypes of melanoma.  A question for further 
investigation, then, will be the extent to which NF-κB signaling, as associated with intrinsic 
resistance, shares any functional overlap with the putative NF-κB modules of dependency 
identified in our shRNA screening.  Regardless of the answer to this question, a comparison of 
genetic essentialities (whether through genome-wide, pooled shRNA screening or by probing the 
NF-κB pathway using a curated arrayed shRNA screening set) between high-NF-κB melanomas, 
high-MITF melanomas, and non-melanoma cancer cell lines should prove useful for identifying 
novel dependencies that could be targeted by future therapeutic regimens and combinations. 
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If the high-NF-κB cellular state presents a challenge to targeted therapy, it possible that, 
conversely, the high-MITF state presents an unexpected opportunity.  Our index finding in 
Chapter 2 was that high MITF expression marks sensitivity to MAPK pathway inhibition.  
Although we have not explored the question here, it is possible that this finding obtains not only 
in BRAFV600-mutant melanoma, but also in other melanoma genotypes.  Several clinical trials 
have been reported for MEK inhibition in NRAS-mutant melanoma; results, however, have 
generally been less impressive than those achieved in BRAFV600-mutant melanoma.  If the 
findings obtained here extend across melanoma genotypes, one might hypothesize that MITF 
expression could be used to identify NRAS-mutant melanomas more likely to respond to MEK 
inhibition.  If this finding bears out, it has the potential to expand significantly the therapeutic 
utility of MAPK pathway inhibition in melanoma. 
Conclusion 
Considered as a whole, this work has employed a series of systematic and hypothesis-driven 
approaches to investigate factors that limit the efficacy and durability of MAPK pathway 
inhibition in melanoma.  A unifying theme from these studies is that the NF-κB pathway may 
have key roles in melanoma not previously appreciated.  In particular, NF-κB signaling appears 
to be modulate and be modulated by both MAPK pathway signaling and MITF regulation, thus 
connecting considerations of targeted therapeutic sensitivity and resistance to those of 
melanocytic lineage identity.  While the present work may heighten interest the NF-κB pathway 
in melanoma, much mechanistic detail also remains to be elucidated.  Significant future work 
will therefore be required to synthesize a comprehensive understanding of the role of NF-κB in 
melanoma dependency, drug resistance, and cellular state. 
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